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Conscious sedation for cataract  surgery done under retro bulbar block 
A Comparative study evaluating the effects of midazolam and dexmedetomidine  
 
ABSTRACT 
Need for the study 
 Cataract surgeries were carried out under local anesthesia  
 A comfortable co-operative stationary patient is a key to achieve good 
result with these patients 
 Hence in this study conscious sedation supplemented  with  
      Peribulbar block  has been carried out and results were observed  
      for   
 better patient cooperation 
 anxiolysis and patient comfortness  
 surgeons satisfaction 
 Stable hemodynamics  
 Lack of complication 
 
Aim and objectives 
 To study the effects of conscious sedation in cataract surgery 
 In this study we compare the effect of midazolam with dexmedetomidine 
and with that of control group 
Method of collection of data 
Prospective randomised double blind clinical control trial 
 
Methodology 
 After obtaining informed written consent, patients will be randomly 
divided into  3 groups  by draw of  lots. 
 Group M-patients receiving midazolam  
      Loading dose-0.03mg/kg 
             Maintenance dose-0.05mg/kg/hr 
 Group D-patients receiving dexmedetomidine  
Loading  dose-0.3mcg/kg over ten min 
             Maintenance dose-0.3mcg/kg/hr 
 Group C-control.  
Loading  dose – plain 0.9% N.S 
             Maintenance dose- plain 0.9% N.S  
 Loading dose is followed by peri bulbar block after 10 min 
 Maintenance dose is given in infusion throughout the procedure and 
infusion is stopped at the end of surgery 
 Supplemental oxygen will not be provided except in case of 
desaturation(SPO2-95%)  
 PARAMETERS MONITORED
 
Baseline B.P, Pulse rate, SPO2. 
Blood pressure, pulse rate,SPO2,R.S,S every 2 min from the time of loading 
dose to the time the surgery was started 
Wong Baker Facial pain rating scale at the time of retrobulbar block 
(4)
 
Intra op vitals-B.P, pulse rate, E.C.G, SPO2 every 5 min 
Ramsay sedation score every 1 min from the time of loading dose till they attain 
the Ramsay sedation score of 3 and every 5 min there after 
Patient movement scale during surgery 
Aldrete recovery score every min after the end of surgery and time to attain the 
score of 10 was recorded
.(11).
 
Patient was shifted to recovery room  after they attain a  Aldrete recovery score 
of 10 
Likert like verbal rating of surgeon’s satisfaction at the end of surgery 
Patient will be asked whether they were aware of ‘unpleasant intraoperative 
events’ in the post operative period 
Post op vitals and Ramsay sedation score every 10 min for 2hrs in the post op  
period 
RESULTS 
We found that conscious sedation was safe and effective in the case of cataract 
surgery and was associated with greater patient ‘s comfort and surgeon’s 
satisfaction  when compared to the surgeries which was done only with retro 
bulbar block alone 
Midazolam in a loading dose of 0.05mg/kg and in a maintenance dose of 
0.03mg/kg was equally effective to dexmedetomidine in the aspect of  patient’s 
co- operation during retro bulbar block and during surgery which was assessed 
by facial pain scale,patient movement scale and surgeon satisfaction scale and 
recall of intra op events 
Midazolam was slightly better to dexmedetomidine in the aspect of better 
hemodynamic profile 
However mean time to reach RSS  of 3 was rapid with dexmedetomidine when 
compared to midazolam. But time to reach Aldrete recovery score 10 was 
prolonged in dexmedetomidine  when compared to midazolam. Both the drugs 
had no significant complications  in the peri operative period 
Conclusion 
We conclude that conscious sedation is safe and effective to practise in the case 
of cataract surgeries and is associated with better patient co operation and 
surgeon comfort when compared to the surgeries which are done with 
retrobulbar block alone. Midazolam and dexmedetomidine are equally effective 
in the aspects of  patient co operation and surgeon’s comfort but midazolam is 
slightly superior to dexmedetomidine in the aspect of better hemodynamic 
profile 
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INTRODUCTION 
 Cataract surgeries were carried out under regional anesthesia(1) 
 A comfortable co-operative stationary patient is a key to achieve 
good result with these patients
(25)
 
 Hence in this study conscious sedation for cataract surgery under 
retro bulbar block had been carried out and result were observed 
for 
 better patient cooperation
(6)
 
 anxiolysis and patient comfortness 
 surgeons satisfaction 
 Stable hemodynamics 
 Lack of complication 
 There has been a recent development in practice of sedation and 
analgesia during ophthalmic procedure particularly cataract surgery  
 Cataract surgeries are performed by placing the patient under 
moderate sedation, a practice that is named as ′conscious sedation′. 
Conscious sedation is required to reduce the anxiety of the patient, 
discomfort and pain during the procedure and to increase the 
cooperation of the patient throughout the procedure and helps in 
improving the performance of the procedure by the 
ophthalmologist.  
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 Various drugs have been used to provide conscious sedation. 
Current drugs include benzodiazepines
(26)
most commonly 
midazolam , opioids 
(27)
 ,ketamine. with or without propofol. 
(2,3,4)
 . 
Newer agents such as dexmedetomidine  and fospropofol are also 
being used nowadays. 
 Midazolam is favoured because of its faster onset and short 
duration of action. It also has high amnestic properties. Midazolam 
is the shortest-acting among the benzodiazepines available.The 
adverse effects of midazolam are hypotension, respiratory 
depression and hypoxemia if given in larger doses and particularly 
when it is combined with an opioid.  
 In recent years, dexmedetomidine is widely being used as an 
alternative to midazolam in conscious sedation. It produces a 
unique form of ′conscious sedation′ in which (patients appears to 
be in a state of sleep but can be aroused readily) with good 
analgesic effect and without significant respiratory depression
.(7) 
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AIM OF THE STUDY 
 
The aim of the study is to study the effects of conscious sedation in            
Cataract surgery .In this study we compare the effects of midazolam with 
dexmedetomidine as conscious sedation and with that of control group 
where no conscious sedation is employed 
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DEFINITION OF CONSCIOUS SEDATION 
 
Conscious sedation is defined as a state in which the patient will be 
in a depressed level of consciousness and tolerate unpleasant procedures 
while maintaining oxygenation, airway control and cardio vascular 
function.  
 
Nowadays it is preferred in many of the day care
(29)
 surgeries like 
cataract surgeries, cholangio pancreatography, dental procedures, and 
minor procedures during trauma care. 
 
This procedure has lead to lesser duration of hospital stay with 
lesser incidence of post operative complications. Conscious sedation has 
been even in paediatric population in number of day care procedures 
which is associated with better patient co operation in case of children. 
 
 
 
 
  
5 
 
ASA CLASSIFICATION FOR SEDATION 
(25) 
 
Conscious sedation comes under the group of moderate sedation as 
per ASA continuum of sedation 
 
Minimal 
sedation 
Moderate 
sedation 
Deep 
sedation 
General 
anaesthesia 
Responsiveness 
Normal to 
verbal 
stimulus 
Purposeful 
response to 
verbal or 
tactile 
stimulus 
response to 
repeated or 
painful 
stimulus 
Unarousable to 
painful 
stimulus 
Airway unaffected 
No 
intervention 
required 
Intervention 
maybe 
required 
Intervention 
often required 
Ventilation unaffected Adequate 
May be 
inadequate 
Frequently 
inadequate 
Cardio resp 
function 
unaffected 
Usually 
maintained 
Usually 
maintained 
May be 
impaired 
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The guidelines for ambulatory anaesthesia and surgery for conscious 
sedation used by the American Society of Anaesthesiologists specifies 
following needs: 
 A physician who has license should always be present while the 
patient is getting treatment, recovery and discharge.                                                                                                                                                                                                            
  The facility must possess good equipments and must follow the 
local, state and federal laws applicable for operations. Attendance 
staff should always be adequate enough to meet facility and patient 
needs  
 The physicians, other practitioners and nurses should be                                                                                                            
duly qualified and licensed. 
 The physicians in the facility who provide medical care to patients 
should be collectively organized into a medical staff. This group of 
facility will take the responsibility for credential review, quality 
assurance, privileges delineation and responsibilities and peer 
review. The availability of the personnel and equipment must be 
adequate so that it would be easy to tackle emergencies. To handle 
the transfer of unanticipated patient to an acute care hospital the 
facility must have established procedures and policies. 
 
7 
 
 The patient care as per the American Society of Anaesthesiologists 
Guidelines for Surgery and Ambulatory Anaesthesia for conscious 
sedation shall include:  
  Instructions and preparation of patients should be done 
preoperatively 
 A physician should take appropriate history from the patient and do 
physical examination  prior to sedation 
 Under the direction of a qualified physician or he himself  shall 
administer the procedural sedation 
 The appropriate personnel from anaesthesiology shall always 
administer general anaesthesia. 
 The criteria for patient discharge is under the responsibility of a 
physician 
 The written postoperative instructions and follow-up instructions 
must be provided with patients. 
 The facility must maintain   accurate, current and confidential 
medical records. 
 Physiologic Monitoring of the patient 
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The American Society of Anaesthesiologists (ASA) outlines certain 
important areas for patient monitoring while in moderate or deep 
sedation.   
 Level of Consciousness 
Analgesia is considered as an excellent guide actually to assess the 
level of consciousness. By means of monitoring this level of 
consciousness, it can help in finding any adverse drug responses or 
reactions so early which is definitely helpful in treating patients quickly 
in a timely manner. Thereby this assessment is a great gift in reducing 
risks of patients for both moderate and deep sedation. A patient who is 
under moderate sedation should be capable of responding to verbal 
commands and also to the light tactile stimuli. Whereas more profound 
stimuli will be required to produce the response in the case of patient in 
deep sedation. That too the response is only reflex withdrawal due to 
those painful stimuli which clearly denotes that patient is on deep 
sedation and bordering on general anaesthesia. 
 Pulmonary Ventilation: 
  Respiratory depression is the most common primary causative 
factor of morbidity often in association with sedation and analgesia. This 
is referred as drug-induced respiratory depression. These kind of adverse 
outcomes possibly can occur. In order to reduce this risk simply we have 
to monitor the ventilatory function. This is achieved by mere observation 
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or auscultation which includes sensation of exhaled air, observing 
abdominal or chest excursions of patient and thoracic palpation. During 
moderate and deep sedation Capnography monitoring is used
(20).
  In a 
circumstance of patient being separated from the caregiver of facility then 
we may have application of using automated apnoea monitoring.  Pulse 
oximetry  cannot be used as a substitute  for  ventilatory  function  
monitoring. This is because  oxygenation  and  ventilation processes  are  
separate  physiologic  processes. 
Oxygenation: 
The adverse  events  include  cardiac  arrest  and  death may  occur  
rarely due to hypoxemia. But  these  adverse  events can  be  reduced  
greatly  by  the  usage  of  pulse  oximetry  as  it gives  early  alarms  in  
detecting  the  hypoxia. Pulse  oximetry  is  very  effective  in  the process  
of  detecting  hypoxemia  while the patient is in sedation  rather  than  by  
clinical  assessment  alone. 
Hemodynamics: 
 Monitoring  vital signs  in  a  regular  manner  decreases  the  
occurrence  of  adverse  outcomes  when  the  patient  is  in   moderate  or  
deep  sedation. Analgesic  and  sedative  agents  may often  interfere  
appropriately  with  autonomic  compensation    for stressors  and  
hypovolemia.  On the  other  hand, if  the  sedation given is  inadequate  
then it  may  develop  dangerous  stressor  responses  like  hypertension  
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and  tachycardia. These  likely  complications  may  be  decreased  by  
means  of  early  detection of  blood pressure  and  heart rate  changes  
occuring  in patients , otherwise  these  complications  can  lead  to  some  
serious  problems. Vital  signs  should  be  carefully  monitored  timely 
for  every  3-5 mins   once  the  patient  established  a  stable  level  of  
sedation.  Continuous  monitoring  of  electrocardiogram (ECG)  is  very  
much  useful  in  reducing  the  risks of  patient  during  deep  sedation  
and  also  for  the  patient  with  high risks  such as  significant  
dysrhythmias  or  cardiovascular  disease.  In normal  risk individuals  
with  moderate  sedation  there  is  no  clear  idea  in  supporting  the  use  
of  electrocardiography.       
Standard  Monitoring: 
 The  parameters  used  in  standard  monitoring  for  the  sedated  
patients  as  specified  in  ASGE  comprise  of  measurement  and  
recording  of  following: 
 Heart  Rate 
 Oxygen  Saturation 
 Blood  Pressure 
 Respiratory  Frequency  and  Ventilation 
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Recovery  and  Discharge: 
There  is a  purpose  of  post sedation  monitoring  to  make  sure  
that  patient  has  returned  back  to  normal  acceptable  level  of  
functioning  before  getting  discharged. Recovery  and  discharge  
depends  upon  many  factors  such  as  length and  type  of  procedure  
performed, age and  physiologic  condition  of the  patient,  quantity  and  
the  kinds  of  sedative or  analgesic  agents  administered and  presence  
of  any  procedural  complications. Consciousness  level, oxygenation , 
hemodynamic  parameters  and  pain level  should  be  measured at  
regular  time  intervals  until  all  returns  to  baseline  value. If  reversal  
agents  such as  naloxone  and  flumazenil  ( short duration of  action)   
are  used  then  it  may  require  a more  extended  monitoring  time 
period  ( up to  2  hours to reverse ). 
Post Sedation  Monitoring: 
 Steps  following  the  procedure  consist of : 
 Monitoring  should  be  continued  until  vital  signs  are  within  
normal  acceptable  limits  and   consciousness  returns  to  
baseline. Aldrete Score , a  standardized  discharge  scoring  
system  should  be  applied  to  determine  patient‟s  recovery. 
 Measurement  of  respiratory rate, heart rate, pulse oximetry  and  
blood  pressure  at least  for  every  5 minutes  during  recovery. 
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 Resuscitation  equipment  and  well trained  individual  should  be  
available  for  managing  complications  throughout  recovery. 
 A  patient  is  suitable  for  discharge  if  he or  she  is  able to  walk 
and  dress  independently  or  when  all  physiologic  criteria  are  
met. Upon  discharge, patients  need  to  get  instructions  regarding  
medications and  follow-up. A  patient must  be  discharged  only  
with  the  care  of  a  responsible  person  to  accompany  him  
home. 
Risks  and  Complications: 
Respiratory  Depression: 
For  suspected  or  confirmed  cases follow the steps 
 Stimulate  to  wake up  and  take  deep  breath 
 If  no  response,  go  for  chin lift  and  jaw thrust  for  patent  
airway. 
 Administer  antagonists – Naloxone  for  opioids  and  flumazenil  
for  benzodiazepines. 
 If  still  no  response,  then  go  for  bag  mask  ventilation  and  
then  oropharyngeal  airway. 
 At last  ET tube  insertion  or  Laryngeal Mask  Airway  should  be  
considered. 
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Cardiac  Complications:      
 During  procedural  sedation, cardiac  arrhythmias  can  occur. 
 Sedation  can  cause  both  hypotension  and  hypertension. 
Paradoxical  Reactions
(5)
 : 
A  state  of  excitement can be  seen  with  benzodiazepines as  
sedation  in  some  patients (less than 1% cases). These include  
movement, excessive talkativeness  and  emotional  release. 
Predisposing  Patient  Characteristics: 
 Genetic  predisposition 
 Young  and  advanced  age 
 Alcoholism / drug abuse 
 Psychiatric  and/or  personality  disorders 
 Management: 
 A  benzodiazepine  antagonist,  flumazenil  is  effective  in 
minimizing  the  side  effects. 
 In  few  cases,  droperidol  resolves it. 
 But  often, propofol  is  administered  for  better  control. 
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CATARACT SURGERY 
Cataract is a disease of the lens leading to decrease in transparency 
due to degenerative changes leading to breakdown of tissues and 
„clumping of proteins‟. 
It is more common in the old age due to aging process and it 
characterized by progressive loss of vision 
Various treatment options are available for cataract surgeries like  
Small incision cataract surgery 
Extra capsular cataract surgery 
Phaco emulsification 
Most of the procedures are being carried out under regional blocks 
like retro bulbar block or peri bulbar block with or without being 
supplemented with conscious sedation 
It is also carried out under topical anaesthesia with local anesthetic 
agent and it is also usually supplemented with sedation. 
Many of the surgeons experience better patient co operation and 
good working condition as it is associated with lesser patient movement 
during the procedure and also patients experience less anxiety during the 
surgery 
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PHARMACOLOGY OF MIDAZOLAM
(23)
 
Midazolam is a short acting benzodiazepine. It has all five 
properties which is characteristic of a benzodiazepine such as anxiolysis, 
sedation, anti convulsant, sedation, anticonvulsant action, skeletal muscle 
relaxation and anterograde amnesia. 
 
STRUCTURE- 
Midazolam is a water soluble benzodiazepine with an imidazole 
ring in its structure that accounts for its stability in aqueous solutions and 
rapid metabolism 
 
MIDAZOLAM (C13 H13 Cl FN3) 
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Metabolism  
Midazolam has absorption through G.I.T and rapid passage across 
blood brain barrier. It is extensively bound to plasma protein that is about 
96-98%. 
Midazolam has shorter duration of action due to high lipid 
solubility which causes rapid redistribution and also causes rapid hepatic 
clearance. The elimination half life is 1 to 4 hours and the volume of 
distribution is 1-1.5L/kg. 
Clearance of midazolam is shorter than  diazepam and hence it can 
be safely used as infusion. 
 
DOSAGE AND DURATION 
Dose for sedation: - 0.01-0.05mg/kg 
Maintenance infusion dose: - 0.02 to 0.05mg/kg loading followed 
by 0.01-0.05mg/kg/hr 
Onset of action – 30 to 60 sec 
Time to peak effect: - 3 to 5 min 
Maximum Duration of sedation: - 90 min 
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GABA RECEPTORS 
They are special receptor group chiefly responds to the action of 
Gamma-Amino Butyric Acid (GABA), an inhibitory neurotransmitter in 
central nervous system. They are divided into two namely  GABA-A and 
GABA-B.     
 
GABA-A Receptors: 
They are ligand gated ion channels also called as ionotropic 
receptors. They are quick in their inhibitory action. This super family has 
many members which include GABA-A receptors, nicotinic acetylcholine 
receptors, 5-HT3 receptors and glycine receptors. They all have a 
characteristic loop formation between two cysteine residues mainly by a 
disulphide bond. 
 
Mechanism of Action 
  Binding of agonists to their binding sites in the extracellular area of 
receptor results in conformational change leading to opening of chloride 
ion channels. Their increased influx causes reversal potential of  -65mV  
in neurons, thereby inhibiting the firing of new action potential. 
Ultimately this results in the sedative effects of the GABA-A agonists. 
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Distribution 
  They are present mainly in many parts of central nervous system. 
But they are also found in leydig cells, placenta, immune cells, bone 
growth plates, liver  and various endocrine tissues. These receptors can 
influence cell proliferation. 
Structure and Function 
The most common type of structure is a pentamer consisting of 2 
alpha, 2 beta and a gamma subunit . But in humans several subtypes are 
there include 
Alpha subunit- 6 types as  GABRA(1,2,3,4,5,6) 
Beta subunit - 3 types as GABRB(1,2,3) 
Gamma subunit - 3 types as GABRG(1,2,3) 
Delta subunit as GABRD,  
 
GABA site - the interface between alpha and beta subunits is 
considered as GABA site. Chiefly Gamma-Amino Butyric Acid (GABA)  
and other agonists exert their inhibitory action in this site. Their 
inhibitory response is very quick due to opening of chloride channels and 
their increased influx stops generating new potential. This leads to early 
part inhibitory post-synaptic potential (IPSP). 
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Benzodiazepine site (BZD site) 
The area interface between alpha and gamma subunits of  GABA-
A  receptor is referred as BZD site. Inosine is the endogenously available 
ligand that exerts its action on this site. 
GABA-A rho receptor. 
This is a variant in GABA-A family. Now it is considered as 
subfamily. These are present in retinal bipolar cells. They are not 
sensitive to benzodiazepines and barbiturates. 
GABA-B Receptor 
They are G-protein coupled receptors, also called as metabotropic 
receptors. Their response to gamma-amino butyric acid (GABA) is slow. 
 
ACTION OF MIDAZOLAM ON GABA A RECEPTORS 
 
Midazolam acts on BZD binding site on GABA A receptors. 
BZD receptors are found in high density in cerebral cortex, 
cerebellum, hippocampus, substantia nigra and in lower density in lower 
brain stem and spinal cord. 
Midazolam binds to BZD receptors and produces conformational 
changes which increases the binding affinity of GABA to the receptor 
and thereby facilitates GABA mediated chloride channel opening and 
causes hyper polarization of membranes. It  has GABA mimetic and 
GABA facilitatory effect. 
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Sedation, anterograde amnesia, and anti convulsant properties are 
mediated by α1 subunit of GABA A receptor while anxiolysis and muscle 
relaxant are mediated by α2 subunit of GABA A receptor. 
 
Effect of the drug is based on proportion of receptor occupancy. 
20% receptor occupancy is found to be sufficient to produce anxiolysis, 
30% to 50% occupancy is needed for sedation and unconsciousness is 
produced in more than 60% of receptor occupancy. 
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METABOLISM 
Metabolized by hepatic enzymes mainly cytochrome 
P450.Principal metabolite is 1-hydroxy midazolam which is half as potent 
as midazolam and is excreted by kidneys. 
Clearance is not altered in renal failure because of high hepatic 
clearance Clearance is delayed in obese patients 
 
DRUG INTERACTIONS 
Metabolism is slowed in the presence of drugs like cimetidine, 
erythromycin, antifungals and calcium channel blockers which inhibit 
cytochrome P-450 enzymes. 
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Fentanyl is also metabolized by cytochrome P-450 and hence 
clearance of midazolam is delayed in the presence of fentanyl. 
It decrease the MAC of volatile agents 
 
PHARMACODYNAMICS- 
Effect on CNS- 
Midazolam - 
Decreases cerebral metabolic oxygen requirement 
Decreases cerebral blood flow 
Produces little or no chance in intra cranial pressure. Hence can be 
used for induction in intra cranial pathology 
Its anticonvulsant property is used in status epilepticus 
Effect on CVS
(19)
 
It produces decrease in B.P and heart rate is decreased 
Cardiac output is not affected and decrease in B.P is due to 
decrease in systemic vascular resistance. 
But due to a plateau in plasma concentration there is a ceiling 
effect for this decrease in B.P 
 
EFFECT ON RESPIRATORY SYSTEM 
In a dose of 0.15mg/kg iv it produces dose dependent decrease in 
ventilation. 
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Causes apnoea in larger doses that is above 0.15mg/kg.Depress 
swallowing reflex and decreases airway reactivity. 
 
CLINICAL USES 
PREMEDICATION 
It is used as premedication orally in the dose of 0.5mg/kg 30min 
before surgery which provides significant anxiolysis 
INTRAVENOUS SEDATION
(9)
 
Onset of sedation is rapid and is associated with lesser incidence of 
hemodynamic instability and respiratory depression if midazolam is 
administered alone. But the incidence of hemodynamic stability and 
respiratory depression is higher if used along with other sedatives and 
opiods. 
Patient usually remains awake when the maintenance infusion is 
stopped at the end of the procedure. 
Hence it is used for sedation either as intermittent dosing or 
continuous infusion in I.C.U as well in minor procedures. 
 
AMNESIA 
It also has the advantage of amnesia. In a plasma level of 50 ng/ml 
the patient remains arousable and amnestic. 
Dose required to produce amnesia is 0.5-0.75mg/kg 
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The duration of amnesia after anesthetic dose is 1-2 hours and is 
lesser if only sedative dose is used. They lack analgesic property. 
 
INDUCTION 
In a dose of 0.05-0.1 mg/kg they are used as inducing agent in 
general anaesthesia. But it does not reduce the increase in heart rate and 
B.P which is found to be associated with tracheal intubation. 
 
 MAINTENANCE OF ANESTHESIA 
Due to high hepatic clearance and shorter duration of action the 
plasma level of the drug falls. Hence midazolam has to be given either as 
intermittent bolus or continuous infusion following loading dose to 
maintain the plasma level of the drug. 
 
NAUSEA AND VOMITING PROPHYLAXIS 
Midazolam reduces nausea and vomiting in a dose of 0.75mg/kg is 
and need for rescue anti emetics is reduced 
 
RECTAL MIDAZOLAM 
Rectal midazolam is used as a preanesthetic medication for 
children and the sedative dose is 1.0 mg/kg. 
 
NASAL MIDAZOLAM 
Intranasal midazolam may be used in combination with other drugs 
in diagnostic and short surgical procedures in children. A dose of 0.2 
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mg/kg-0.3 mg/kg (5 mg/ml, IV solution) in a 1-ml syringe was given.  
Cardiovascular stability was found to be excellent and no respiratory 
depression was evidenced. 
The mean recovery time was 40 min in this noninvasive method of 
deep sedation. 
 
SIDE EFFECTS 
Incidence of venous irritation and thrombo phlebitis is less because 
of its aqueous solubility. Disturbing side effects are respiratory 
depression and prolonged emergence if administered in larger doses. 
Antagonist used to reverse the midazolam  is flumazenil. 
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PHARMACOLOGY OF DEXMEDETOMIDINE
(24) 
 
Dexmedetomidine is a α2 agonist with 1600 times more selectivity 
for α2 receptors when compared to α1 receptors. It is a d-enantiomer of 
medetomidine which is used as sedative and analgesic in veterinary 
medicine for many years. 
 
STRUCTURE 
It belongs to imidazole subclass of α2 agonist. It is freely soluble in water. 
 
DEXMEDETOMIDINE (C13H16N2.HCL) 
Pharmacokinetics 
Dexmedetomidine is rapidly redistributed and extensively 
metabolized in liver and excreted in urine and feces. 
It undergoes hydroxylation and n-methylation followed by 
conjugation. It is 94% protein bound. 
It exhibits non linear pharmacokinetics. 
It produces marked vasoconstriction in large doses. 
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Dosage and duration 
Elimination half life – 2  to 2 and half hours
(7) 
Context sensitive half time- 4  to 5 minutes after stopping infusion 
of 10 min 
Loading dose 0.3-1mcg/kg over 10-20 min 
Maintenance dose – 0.1-0.7mcg/kg/hr 
MECHANISM OF ACTION 
Alpha 2A Receptor 
Alpha2 adrenergic receptor is a G-protein coupled receptor with Gi 
heterotrimeric G-protein. It has 3 subtypes alpha 2A , 2B and 2C. Normally 
through these receptors only catecholamines (epinephrine & nor 
epinephrine) are in signal connection with Central and peripheral nervous 
system. 
Alpha2A receptor also called as ADRA2A which also denotes gene 
encoding the receptor is located in chromosome 10. These receptors are 
located in central nervous system that includes locus coeruleus of 
brainstem, midbrain, hippocampus, hypothalamus, cerebral cortex, 
cerebellum, spinal cord. 
Mechanism of Action 
 The alpha2 subunit present in inhibitory Gprotein - Gi gets 
detaches and attaches with adenylyl cyclase leads to inactivation of 
adenylyl cyclase results in decease in cAMP production. Therefore there 
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is no action of protein kinase A on phosphorylase kinase resulting in  no 
phosphorylation in glycogen breakdown. 
Role 
 It plays an important role in regulation of neurotransmitter release 
from sympathetic nerves and from adrenergic neurons in central nervous 
system especially presynaptic inhibition of neurotransmitter release. But 
most alpha2 receptors are present postsynaptically to noradrenergic ends, 
thus it helps in function of norepinephrine. Many postsynaptic alpha2A 
receptors have significant effects on brain functions. For example alpha2A 
receptor in prefrontal cortex helps in regulating higher cognitive function.  
Agonists: 
            Dexmedetomidine 
            Clonidine 
            Guanfacine 
Antagonists: 
             BRL-44408 
             Asenapine 
 
DEXMEDETOMIDINE ACTION ON α2 RECEPTORS
(24) 
Dexmedetomidine acts on α2 receptors. 
Three types of α2 receptors are available. α2A is located in periphery 
and α2B and α2C are located in brain and spinal cord. 
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 Post synaptic α2 receptors in periphery produces vasoconstriction 
and presynaptic α2 receptors produces vasodilatation by inhibiting 
norepinephrine release. 
 Overall response of α2 agonist is due to its effect on CNS and 
spinal cord. The receptors are involved in sympatholysis, sedation 
and antinociception . 
 Dexmedetomidine acts by enhancing the endogenous sleep 
producing pathways. It produces decrease in the activity of 
projections of locus caeruleus to the ventro lateral preoptic nucleus. 
This increases GABAergic and galanin release in tubero 
mammilary nucleus producing decrease in histamine release in 
subcortical and cortical projections and thereby induces sleep 
 It decreases the central sympathetic outflow and this is responsible 
for its effect in cardio vascular system in reducing B.P and pulse 
rate 
 
PHARMACODYNAMICS 
EFFECTS ON CENTRAL NERVOUS SYSTEM 
SEDATION 
Dexmedomidine produces sedative and hypnotic effect by its 
action on α2 receptors in locus caeruleus and its analgesic action by α2 
receptors in locus caeruleus and within spinal cord. 
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Patients in I.C.U set up is found to be arousable and comfortable 
even if tracheally intubated when dexmedetomidine is used as a sedation. 
It is therefore used to perform “daily wake up” test while weaning 
the patient off the ventilator in I.C.U patients. 
If produces profound sedation and can be used as a total i.v 
inducing agent if used in a dose ten times that of normal sedative dose 
Because of its short duration of action it is said to have no addiction 
potential, tolerance and dependence. 
ANALGESIA 
Main site of its action for analgesia is said to be in spinal cord and 
hence used in epidural and intra thecal administration. 
When given intravenously it is said to have narcotic sparing effect. 
However it is not found to be effective as a sole analgesic agent but found 
to enhance the analgesia produced by other analgesics. 
By reducing the central symphathetic outflow and by reducing 
CMRO2 it is said to have neuro protective effect on CNS but this aspect is 
still under investigation. 
Cortical evoked potentials and its amplitudes and latencies were 
minimally affected by dexmedetomidine and hence used in cases where 
neurological monitoring is used. 
It is also said to reduce opiod induced muscle rigidity. 
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EFFECT ON RESPIRATORY SYSTEM 
Dexmedetomidine at concentration producing significant sedation 
reduces minute ventilation but retains the slope of ventilatory response to 
increasing carbon dioxide. 
PaCo2 increases mildly with dexmedetomidine but it reach a 
plateau after the first increment. It also exhibit a hypercarbic arousal 
phenomenon which is seen during normal sleep and it is a safety feature 
However ventilation is minimally affected in a dose which is used for 
conscious sedation. 
EFFECTS ON CARDIO VASCULAR SYSTEM 
It blunts the central symphathetic outflow thereby decreasing heart 
rate and blood pressure.It also decreases contractility of the heart. 
If given in a dose of more than 2mcg/kg it is found to have 
biphasic response. An initial increase in B.P occurs due to its action on 
peripheral receptors but returns to baseline in 15 min and B.P gradually 
reduces to 15% below baseline in one hour. 
With I.M injection this initial increase in B.P is not seen and heart 
rate and B.P remained within 10% of baseline 
The incidence of hypertension and bradycardia is based on loading 
dose administration. Omitting the loading dose and not giving more than 
0.5mcg/kg/hr reduces the incidence of hypotension. 
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Giving the loading dose over twenty minutes also minimizes the 
transient hypotension and Bradycardia. 
The perioperative use of dexmedetomidine is found to reduce the 
incidence of perioperative myocardial ischemia. 
No rebound effect is noted when dexmedetomidine infusion is 
discontinued after 24 hours. 
 
CLINICAL USES 
INTENSIVE CARE UNIT 
It is used for sedation in mechanically ventilated patient. But 
vigilant monitoring of patients vitals and respiration is needed. 
It is used in the withdrawal syndrome of alcohol, narcotics and 
benzodiazepines as it does not have dependence and tolerance. 
F.D.A recommended the use of dexmedetomidine infusion for 24 
hours or less. 
ANAESTHESIA 
Used in attenuation of stress response in laparoscopic procedures. 
Used as a premedication in reducing the stress response to 
intubation and also to attenuate intra op stress response where major 
hemodynamic fluctuation is anticipated as such in case of  
hyperthyroidism , pheochromocytoma and in coronary heart disease 
patients. 
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Average infusion required to maintain the B.I.S value of 70-80 is 
0.7mcg/kg/hr. 
It reduces the intra op requirement of opiods and analgesic 
requirement by around 50%. 
It reduces the MAC of volatile agents. 
 
SIDE EFFECTS 
 Bradycardia and hypotension if given in large doses (>1mcg/kg) or 
in rapid infusion rate (< 10 min) 
 Hypertension if loading dose is given more than 1mcg/kg 
 Dry mouth due to reduction in saliva secretion 
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RETRO BULBAR BLOCK 
 
It is a regional anesthetic nerve block where local anesthetics 
loaded in a syringe is injected in the retro bulbar space that is behind the 
globe of eye. This block produces akinesia of extra ocular muscles by 
blocking cranial nerves ll, lll, Vl  thus movement of the globe is 
prevented. Cranial nerve lV which is present outside the muscle cone also 
gets blocked due to local anesthetics diffusion. Further it blocks ciliary 
nerves so that sensation to conjunctiva, cornea and uvea is lost. This 
block is most frequently used in cataract surgery and also in other 
intraocular surgeries. 
 
Technique 
Before commencing the technique, resuscitation instrument, 
careful observation and assistant help must be available . Patient  is 
placed in sitting or supine position with the head  in neutral position. A 
22-27 gauge, 3cm long needle with syringe loaded with local anesthetics 
is given at inferolateral border of bony orbit, goes backwards till reaches 
centre of the globe and then have to pass medially towards the apex of 
orbit. If some restriction is felt when the needle tip is passed through the 
muscle cone , stop moving the needle. After aspirating for blood,  local 
anesthetics is injected and needle is taken out. Usually 2% lidocaine 
and/or 0.5% - 0.75% bupivacaine are used as local anesthetics. Avoid 
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mixing LA with epinephrine for vasoconstriction, as it can possibly lead 
to central retinal artery occlusion. Often an enzyme, hyaluronidase is used 
with LA as it fastens the spread and action of the drug. If akinesia and 
anesthesia occurs quickly in minutes then the block is successful. This 
block can be used in corneal transplantation but it may additionally 
require facial nerve block. It does not block orbicularis oculi muscle. 
Adverse Effects and Complications 
 It may be local or systemic. The local ocular effects are 
development of hematoma, damage to optic nerve, and any perforation 
injury to the globe ultimately leading to blindness.  
 Systemic effects-   
Toxicity of local anesthesic drug can occur. Injury  to brainstem 
may also happen. Stimulation of oculocardiac reflex. 
  Other than that patient feels uncomfortable during the technique 
because of needle sensation. Recently peribulbar block has been 
increasingly used to reduce these complications 
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RETROBULBAR BLOCK 
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REVIEW OF LITERATURE 
 
HASEN KV et all
(38)
 
A Retrospective study was conducted in 85 Patients in which the 
hospital records of all 85 patients were collected. Patients undergoing 
aesthetic procedures were included and the surgery was performed under 
intravenous sedation. The author had a hypothesis that the difference in 
the outcome parameters was not significant between the groups. All 
records of patients undergoing surgery under a conscious sedation using 
intravenous midazolam and fentanyl were evaluated and compared with 
the second group who undergo aesthetic surgery using propofol infusion.. 
A questionnaire evaluating operative and peri operative outcome such as 
pain, nausea, vomiting and anxiety were analysed. No significant 
statistical difference exists between the groups regarding aesthetic 
procedure, duration of procedure and ASA grouping between the groups. 
Hypotension was observed in the propofol group but no patient required 
intensive treatment other than just reducing the dose of sedative agent and 
increasing i.v fluids. The amount of rescue analgesic needed was higher 
in propofol  group when compared to midaz/fentanyl group. “Recall of 
unpleasant intraoperative agents” were higher in midaz/fentanyl group 
when compared to other group (17 percent versus 3 percent, p = 0.007). 
No significant difference in the intraoperative pain, nausea and anxiety 
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between the groups.  The propofol group experienced significantly more 
nausea in the recovery room (p = 0.002), nausea at the time of discharge 
(p = 0.009), and nausea the evening after the operation (p = 0.013).patient 
satisfaction appears to be same in both the groups. This study concluded 
that there no difference is found to exist the sedative agents used and they 
have better safety profile for its use in aesthetic procedures. 
 
ROLO.R et al
(36)
 
This study compared the effect of midazolam as a sedative in 
bronchoscopy when compared to that of placebo group. 
A randomised double blind prospective trial was done in 100 
patients who underwent fibre optic bronchoscopy (F.O.B) .Two groups 
were assigned. Midazolam was given to patients in Group 1 in a dose of 
0.05mg/kg and saline solution was given to  Group 2.. Patient anxiety 
level was evaluated with The Hospital Anxiety and Depression Scale 
(HADS-A). Patient‟s main concern like fear and apprehension were 
evaluated both before and after the procedure using a subjective 
questionnaire. 
The results of the study were there is significant increase in 
intraoperative blood pressure in group 1 when compared to group 2 (p – 
0.003). Incidence of cough and dyspnoea were reduced in group 1 when 
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compared to group 2. Incidence of nausea and pain in the immediate post 
operative period had no significant difference 
This study concluded that midazolam has better patient comfort 
and tolerance than place Bo group during the procedure of fibre optic 
bronchoscopy .Hence it can be used for sedation in F.O.B with a good 
safety profile and with lesser incidence of complication. 
 
Waleed M.A.Al Taher et al.,
(37)
 
A study was conducted in 60 paediatric patient who underwent 
dental procedures as an outpatient procedure in dentistry department. All 
children belonged to the age group between 4 and 10 years.  
Group I received dexmedetomidine in a dose of  1μg/kg  over 
15min followed   by maintenance infusion of 0.45μg/kg/h . Group II was 
given midazolam 0.04 mg/kg and propofol as 1 mg/kg over 10 min 
followed by 4 mg/kg as maintenance infusion. Vitals parameters such as 
heart rate, blood pressure, SPO2 and respiratory rate were measured 
every 5 min. Onset of the sedation, duration of procedure, recovery 
profile, time for rescue analgesia evaluated. 
Result of the study showed that   time for the onset of sedation was 
prolonged in groupI. Recovery time was shorter in dexmedetomidine 
group when compared to that of midaz+propofol group.  The dose of 
rescue analgesic is also reduced in group I . 
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Study showed dexmedetomidine is safer in paediatric patients and 
can be used as sedation for dental procedures.  
Patients who were given dexmedetomidine were found to be 
associated with faster recovery when compared to that of the patients who 
received the combination of midazolam and propofol. 
 
CHAMORRO  et al., 
The study compared the effectiveness of propofol and midazolam 
in the sedation of mechanically ventilated patient in the intensive care 
unit. 97 patients who required mechanical ventilation for medical 
problems and needed sedation for a minimum of 48 hours and a 
maximum of 5 days were included.  Propofol was given as 2mg/kg and 
midazolam as 0.2mg/kg.  1.8mg/kg/hr of propofol and 0.2 mg/kg/hr of 
midazolam given as maintenance dose. All the patients were monitored 
continuously for blood pressure, pulse rate, SPO2.Patients were noted for 
the signs of ventilator asynchrony like agitation, increase in heart rate, 
increase in airway pressure and abnormal restless movements. 
In the results of the study there was no significant difference in the 
requirement of opiod and muscle relaxant. Patient ventilator synchrony 
was better with propofol when compared to that of midazolam. Patient 
given propofol awake more rapidly than midazolam ((23 +/- 16 mins vs. 
137 +/- 185 mins, respectively, p < .05).  
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Incidence of hypotension was more with propofol than midazolam 
during maintenance period and it required the reduction of propofol 
infusion rate and increase in intra venous fluid administration. 
The conclusion of this study is that both propofol and midazolam is 
effective for sedation of mechanically ventilated patients in I.C.U with 
propofol having the advantage of prompt recovery and midazolam having 
the advantage of lesser incidence of hypotension. 
 
PRIYANKA SETHI et al.,  
A randomised controlled trial was done to compare the effect of 
midazolam and dexmedetomidine as a conscious sedation in retrograde 
cholangio pancreatography.The study was conducted in 60 patients 
whose age group range between 18-40 years. 
 
Group M was given midazolam as 0.03mg/kg iv and 
supplementation of 0.5mg given until they attain Ramsay sedation scale 
of 3. Group D received inj.dexmedetomidine 1mcg/kg iv and  
maintenance infusion of 0.5mcg/kg/hr iv was given until they reach a 
Ramsay sedation score of 3. All the patients received inj.fentanyl 
1mcg/kg. Vital parameters like blood pressure, pulse rate, facial pain 
scale, time to attain the Ramsay sedation score of 3 has been studied in all 
two groups during and after the procedure. Time to attain the Aldrete 
recovery score of 9-10 and surgeon satisfaction scale had been evaluated 
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in the recovery room. Incidence of complication during and after the 
procedure was also noted.  
Study showed that blood pressure and F.P.S  dose was lower with 
dexmedetomidine than with group M.There was no significant difference 
in P.R and respiratory rate between the groups. The Aldrete score of 9 
was achieved sooner in group D .than group M. satisfaction scale given 
by surgeon was better with group D. Group D also had higher patient 
satisfaction scale.  
The study concluded that both midazolam and dexmedetomidine is 
effective as conscious sedation in E.R.C.P procedures and 
dexmedetomidine is found to be slightly superior in its effects when 
compared to midazolam. 
RICHARD.R.RIKER et al., 
Double blind prospective randomised trial was done in 68 hospitals 
in 370 medical and surgical patients in the I.C.U . Richmond Agitation 
Sedation Scale and Confusion Assessment Method were used. 
 Midazolam was given as 0.02-0.15mg/kg /hr and 
dexmedetomidine was given in the dose of 0.2-1.0mcg/kg/hr and the dose 
was titrated till the patients attained the RASS score between -2 to +1 
from the time of enrolment to extubation. Time to achieve the target 
RASS score, delirium, ICU stay duration and adverse effects were 
measured as parameters 
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No difference in the time to achieve the target RASS score was 
noted between groups .Incidence of delirium is higher in midazolam 
group. Length of ICU stay was also lower in dexmedetomidine group 
when compared to midazolam group. Group D showed higher incidence 
of bradycardia when compared to group M but non significant proportion 
of people only required treatment. 
The results of the study concluded that there was no difference 
between the groups for attaining the target level of sedation in 
mechanically ventilated patients in I.C.U. However dexmedetomidine 
group experienced lesser incidence of delirium, better ventilator 
synchrony and lesser incidence of hypertension and tachycardia when 
compared to that of midazolam group. But the disturbing adverse effect 
which occurs with the use of dexmedetomidine is bradycardia. 
DHARA A. VYAS et al., 
This study evaluates the effect of dexmedetomidine and midazolam 
which is used as sedation and its effect on hemodynamics during 
modified radical mastoidectomy and tympanoplasty. 50 patients were 
studied and divided into two groups.  
Group D was given Dexmedetomidine as 1µg/kg over 20 min 
followed by  the maintenance  infusion as  0.5µg/kg/hr and Group M was 
given as Midazolam 0.05 mg/kg i.v. followed by the maintenance dose of  
0.01mg/kg/hr .vital parameters like blood pressure ,sedation level and 
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heart rate were monitored. Satisfaction of patient and surgeons were 
monitored using Likert scale No difference observed between the two 
groups with regard to sedation level. There was no difference in the 
diastolic pressure between the groups. But the satisfaction scale given by 
surgeon and patient was higher in group D. Heart rate was lower in group 
D than that of group M. 
The study concluded that dexmedetomidine can be safely used as 
an alternative to midazolam for sedation in E.N.T procedures. 
 
DAVIES FC
1
, WATERS M et al., 
This study compares the safety and efficacy of two doses of oral 
midazolam and the drug induced amnesia was assessed when given as a 
conscious sedation for children who undergo minor procedures in the 
accident and trauma centre. 
A prospective, double blinded, randomised trial was done which 
compares 0.2 mg/kg midazolam suspension with that of 0.5 mg/kg which 
was a higher dose. Children whose parents give consent for sedation of 
minor procedures were selected. Anxiety of the patient was assessed 
using physiological parameters, behavioural anxiety score, parental visual 
analogue scale, and a telephone questionnaire at 2-7 days after the 
procedure. 
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The study concluded that oral midazolam appears to be safe in the 
dose of 0.5mg/kg and is effective in the sedation of children who undergo 
minor procedures in trauma care and it can be considered by A&E 
departments who are dealing with paediatric patients 
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OBJECTIVES OF THE STUDY 
 
The objectives of the study was  
 To evaluate the advantage of conscious sedation in cataract surgeries 
which is done with retro bulbar block 
 To compare the effects of midazolam and dexmedetomidine in 
conscious sedation  
 
The anaesthetic efficacy regarding 
1) Anxiolysis of the patient 
2) Patient‟s cooperation  
 In the placement of retro bulbar block and 
 During the procedure 
3) Hemodynamic stability 
4) Satisfaction of the surgeon 
5)  Recovery profile of  the drugs and 
6) Incidence of complications 
- were noted and compared 
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MATERIALS AND METHODS 
 
After getting approval from the ethics committee prospective 
randomised double blind control trial was carried out in 90 patients. 
Informed written consent was obtained from the patient 
 Patients randomly divided into 3 groups by draw of lots 
Group M-Patients received midazolam 
Loading dose-0.03mg/kg over 10 min 
Maintenance dose-0.05mg/kg/hr 
Group D-Patients received dexmedetomidine 
Loading dose-0.3mcg/kg over ten min 
Maintenance dose-0.3mcg/kg/hr 
Group C-control 
Loading and maintenance dose is given as plain N.S infusion 
All patients are kept N.P.O for six hours 
For all patients age and weight were noted 
In the preoperative assessment room vital parameters like pulse 
rate, blood pressure and baseline investigations like hemoglobin, blood 
sugar, urea and creatinine, CXR and E.C.G were noted. 
Thorough examination of all systems and airway assessment was 
done in all patients. 
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INCLUSION CRITERIA 
Patients who give informed written consent. 
Patients aged between 50 to 70 years. 
 ASA Class I and Class II. 
Patients who weigh between 50-70kgs 
Duration of surgery less than 30 min 
Weight between 45-75 kg 
 
EXCLUSION CRITERIA 
Hypertensive patients 
Patients with renal disorders 
Patients with known C.N.S disorders 
Patients with C.A.D, heart block 
Patients who belong to ASA III and IV 
Patients with anticipated difficult airway 
 
MATERIALS 
Midazolam 5 mg ampoule 
Dexmedetomidine 200 mcg ampoule 
100 ml of 0.9% Normal saline 
2cc syringes 
18 G intravenous cannula 
Infusion pump 
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Monitors- pulse oximeter, N.I.B.P, E.C.G 
In the operating room, appropriate equipment for airway 
management and emergency drugs were kept ready. Patients were shifted 
to operating room. Monitors like pulse oximeter, N.I.B.P and E.C.G were 
connected. Baseline parameters like systolic and diastolic blood pressure, 
pulse rate and oxygen saturation were noted. All the drug preparation 
were made by the Post graduate colleague and both the observer and the 
patient didn‟t know the content of the preparation. 
Loading dose is given to the patients. Patients who belong to group 
M received inj.midazolam in a dose of 0.03 mg/kg i.v and patients who 
belong to group D received inj.dexmedetomidine in a dose of 0.3mcg/kg 
over 10 min. Group C patients received plain normal saline. 
Double blinding – For group M loading dose was given as 
0.03mg/kg iv bolus followed by plain N.S infusion for 10 min and for 
group D loading dose was given as plain Normal saline iv bolus followed 
by infusion of 0.3 mcg/kg over 10 min. 
Loading dose is followed by retro bulbar block after 10 min. 
Peribulbar block was given with a mixture of inj .bupivacine 0.5% 
2.5cc and inj.lignocaine 2% 2.5 cc. 
Surgery was started at the end of 10 min when loading dose was 
completed. 
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Maintenance dose was given as infusion till the procedure ends. 
Group M patients were infused with inj.midazolam 0.05 mg/kg/hr i.v in 
100 ml N.S and Group D Patients were infused with inj.dexmedetomidine 
0.3mcg/kg/hr i.v in 100 ml N.S. Group C patients received plain normal 
saline infusion. 
Supplemental oxygen will not be provided except in case of 
desaturation (SPO2-95%)
(21).
Atropine is given if heart rate falls below 
50/min. 
If M.A.P falls below 30% of baseline intra venous fluids would be 
rushed. Ionotrophic drugs were kept ready. 
 
PARAMETERS MONITORED
(14,15,16) 
 Baseline B.P, Pulse rate, SPO2. 
 Blood pressure, pulse rate,SPO2,R.S,S every 2 min from the time 
of loading dose to the time the surgery was started. 
 Wong Baker Facial pain rating scale at the time of retrobulbar 
block 
(4)
 
 Intra op vitals-B.P, pulse rate, E.C.G, SPO2 every 5 min 
 Ramsay sedation score every 1 min from the time of loading dose 
till they attain the Ramsay sedation score of 3 and every 5 min 
there after 
 Patient movement scale during surgery 
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 Aldrete recovery score every min after the end of surgery and time 
to attain the score of 10 was recorded
.(11).
 
 Patient was shifted to recovery room  after they attain a  Aldrete 
recovery score of 10 
 Likert like verbal rating of surgeon‟s satisfaction at the end of 
surgery 
 Patient will be asked whether they were aware of „unpleasant 
intraoperative events‟ in the post operative period 
 Post op vitals and Ramsay sedation score every 10 min for 2hrs in 
the post op  period 
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FACIAL PAIN RATING SCALE 
 
 
 
0 – NO HURT 
1 – HURTS LITTLE 
2- LITTLE MORE HURT 
3- HURTING EVEN MORE 
4- HURTS A LOT 
5- HURTS WORST 
 
This parameter is measured at the time of retro bulbar block  
Retro bulbar block is given at the end of the loading dose 
Patient‟s pain scale is numbered based on their facial expression at the 
time of giving the block 
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RECALL OF INTRA OPERATIVE EVENTS 
Patients will be enquired whether 
1) They were able to hear the conversation of nurses and surgeon 
while operating 
2) Whether they were aware of the events like moving their body and 
turning their head 
3) Whether they were able to recollect a standard music which was 
played intra operatively 
Patients who were able to recall any one of the above was 
considered to say as „YES‟ 
Patients who were not able to recall all of the above is considered 
as „NO‟ 
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RAMSAY SEDATION SCORE 
 
1 – anxious, agitated 
2 – Co operative, tranquil 
3 – Response to verbal commands.pt will be asleep but arousable 
4- Brisk response to light glabellar tap 
5- Mild response to light glabellar tap 
6 – No response 
 
Ramsay sedation score is measured every 3 min from the time of 
loading dose till the end of surgery and every 5 min in the post operative 
period for two hours 
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PATIENTS MOVEMENT SCALE DURING SURGERY 
1-No movement 
2-Movement with slight effect on surgical field(less than ½ of eye 
outside the microscope) 
3-Movement with moderate effect (more than ½ of eye outside the 
microscope) 
4-Movement with major effect (whole eye outside the microscope) 
 
This parameter was noted by the observer in the television which 
showed the events which was recorded in the operative microscope. 
This was observed till the end of the procedure. 
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ALDRETE RECOVERY SCALE
(11)
 
 
Time to attain the Aldrete recovery score of 10 from the end of 
surgery was recorded 
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Likert like verbal rating scale 
(9,12)
 
1- Dissatisfied extremely 
2- Not satisfied 
3- Satisfied to some extent 
4 – unable to decide 
5- Satisfied to Some extent 
6- Satisfied by the subject 
7-satisfied extremely 
This parameter was measured by asking the surgeon to rate the 
level of his satisfaction as a numerical from 1 to 7 
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OBSERVATION AND RESULTS 
 
AGE DISTRIBUTION 
 
AGE 
 
GROUP 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
  
CONTROL 
 
GROUP M 
 
 
60.83±4.54 
 
61.56±4.86 
 
 
 
0.6 
 
 
 
0.5504(not 
significant) 
 
GROUP M 
 
GROUP D 
 
 
61.56±4.86 
 
60.134±4.89 
 
 
 
0.261 
 
 
0.2610(not 
significant) 
 
GROUP D 
 
CONTROL 
 
60.134±4.89 
 
60.83±4.54 
 
 
 
0.2068 
 
 
0.8369(not 
significant) 
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AGE DISTRIBUTION AMONG GROUPS 
  
 
 
 
The mean age group of group M is 61.56, group D is 60.13, and 
control group is 60.83. 
P value –  Between group M and group D = 0.261 (not significant) 
                 Between control and group M =0.55(not significant) 
                 Between group D and control =0.8369(not significant) 
 
All the three groups are comparable in terms of age 
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SEX DISTRIBUTION 
 
SEX Group M Group D 
 n % N % 
Male 16 53.3% 16 53.3% 
Female 14 46.7% 14 46.7% 
Chisquare value                                       0 
Df                                      1 
p-value 1(not significant) 
 
 
SEX Control Group M 
 n % N % 
Male 14 46.7% 16 53.3% 
Female 16 53.3% 14 46.7% 
Chisquare value 0.2667 
Df 1 
p-value 0.655(not significant) 
SEX Group D Control  
 n % N % 
Male 14 46.7% 16 53.3% 
Female 16 53.3% 14 46.7% 
Chisquare value 0.2667 
Df 1 
p-value 0.655(not significant) 
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SEX DISTRIBUTION BETWEEN GROUPS 
 
 
 
 
The percentage of male patients in group M is 53.3%, group D is 53.3%, 
and control group is 46.7%. 
The percentage of female patients in group M is 46.7%, group D is 
46.7%, and control group is 53.3% 
 P value – between group M and group D = 1 (not significant) 
                 Between control and group M =0.655(not significant) 
                 Between control and group D =0.655(not significant) 
All the three groups are comparable in terms of sex 
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WEIGHT DISTRIBUTION 
 
 
 
Weight 
  
Mean ± Standard 
Deviation 
 
t-Value 
 
p-Value 
  
CONTROL 
 
GROUPM 
 
61.23±5.55 
 
61.66±5.39 
 
 
0.3044 
 
 
 
 
0.7619(not 
significant) 
 
GROUP M 
 
GROUP D 
 
61.66±5.39 
 
61.3±6.17 
 
 
0.2422 
 
 
0.8095(not 
significant) 
 
GROUP D 
 
CONTROL 
 
61.3±6.17 
 
61.23±5.55 
 
 
 
0.0462 
 
 
0.9733(not 
significant) 
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WEIGHT DISTRIBUTION AMONG GROUPS 
(Comparing Weight As Below 60 kg and above 60 kg) 
                                  
 
                                                          
The mean weight of group M is 61.23, group D is 61.66, and control 
group is 61.3 
P value – between group M and group D = 0.7619 (not significant) 
                 Between control and group M =0.8095(not significant) 
                 Between group D and control =0.9733(not significant) 
All the three groups are comparable in terms of weight 
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ASA STATUS DISTRIBUTION 
ASA STATUS 
CONTROL 
(n=30) 
GROUP 
M(n=30) 
 N % n % 
ONE 12 40.0% 15 50.0% 
TWO 18 60.0% 15 50.0% 
Chi square value 0.6061 
Df 1 
p value 0.436(not significant) 
 
 
ASA STATUS 
GROUP 
M(n=30) 
GROUP 
D(n=30) 
 n % n % 
ONE 15 50.0% 13 43.3% 
TWO 15 50.0% 17 56.7% 
Chi square value 0.2679 
Df 1 
p value 0.604(not significant) 
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ASA STATUS GROUP D CONTROL 
 n % n % 
ONE 13 43.3% 12 40.0% 
TWO 17 56.7% 18 60.0% 
Chi square value 0.006 
Df 1 
p value 0.9736(not significant) 
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ASA  DISTRIBUTION AMONG GROUPS 
(Comparison between the distribution of ASA I and ASA II between 
groups) 
 
 
 
The percentage of ASA I patients in group M is 50 %, group D is 43.3%, 
control group is 40% 
The percentage of ASA II patients in group M is 50%, group D is 56.7%, 
and control group is 60% 
 p value – between group M and group D =0.604 (not significant) 
                 Between control and group M =0.43(not significant) 
                 Between control and group D =0.97(not significant) 
All the three groups are comparable in terms of ASA status 
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SYSTOLIC BLOOD PRESSURE 
 
 
Baseline 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
116.37±9.469 
 
113.23±5.021 
 
 
1.6032 
 
 
 
 
0.1139(not 
significant) 
 
GROUP M 
 
GROUP D 
 
113.23±5.021 
 
116.3±9.535 
 
 
1.5604 
 
 
0.1241(not 
significant) 
 
GROUP D 
 
CONTROL 
 
116.3±9.535 
 
116.37±9.469 
 
 
0.0285 
 
 
0.9773(not   
significant) 
 
 
 
Loading 
Dose 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
119.6±9.981 
 
110.31±6.292 
 
 
4.3437 
 
 
 
 
<0.0001(sign
ificant) 
 
GROUP M 
 
GROUP D 
 
110.3±6.292 
 
104.7±12.13 
 
 
2.2486 
 
 
0.0283(signif
icant) 
 
GROUP D 
 
CONTROL 
 
104.7±12.13 
 
119.6±9.881 
 
 
5.2164 
 
 
<0.0001(sign
ificant) 
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Intraop 
 
 
Mean ± Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
121.433±10.59 
 
110.394±6.577 
 
 
4.8496 
 
 
 
 
<0.0001(sign
ificant) 
 
GROUP M 
 
GROUP D 
 
110.394±6.57 
 
99.96±9.06 
 
 
5.0997 
 
 
<0.0001(sign
ificant) 
 
GROUP D 
 
CONTROL 
 
99.96±9.06 
 
121.433±10.59 
 
 
8.3436 
 
 
<0.0001(sign
ificant) 
 
 
 
Postop 
  
Mean ± Standard 
Deviation 
 
t-value 
 
p-value 
  
CONTROL 
 
   GROUP M 
 
 
110.7±6.609 
 
110.99±4.92 
 
 
0.1880 
 
 
 
 
0.8515(not 
significant) 
 
GROUP M 
 
GROUP D 
 
110.99±4.92 
 
116.06±37.6 
 
 
0.7310 
 
 
0.4677(not 
significant) 
 
GROUP D 
 
CONTROL 
 
116.06±37.6 
 
110.7±6.609 
 
 
0.7710 
 
 
0.4438(not 
significant) 
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SHOWING DIFFERENCE IN MEAN SYSTOLIC BLOOD 
PRESSURE BETWEEN GROUPS                   
 
 
 Mean systolic baseline B.P is 113.23(mm of hg) in group M, 
116.3(mm of hg) in group D and 116.37 (mm of hg) in control 
group. p-values between group M and D, group M and control, 
group D and control are 0.1139, 0124, 0.97 respectively which are 
statistically not significant to each other. 
 Mean systolic B.P during loading dose administration is 110.3(mm 
of hg) in group M, 104.7(mm of hg) in group D and 119.6(mm of 
hg) in control group.  p-values between group M and D, group M 
and control, group D and control are 0.02836,< 0.0001, and < 
0.0001 respectively which are statistically significant to each other. 
 Mean systolic B.P during intra op period is 110.39(mm of hg) in 
group M, 99.96 (mm of hg) in group D and 119.6 (mm of hg) in 
control group.  p-values between group M and D, group M and 
control, group D and control are <0.0001,< 0.0001, <0.0001 
respectively which are statistically significant to each other. 
 Mean systolic B.P during post op period is 110.9(mm of hg) in 
group M, 110.7(mm of hg) in group D and 116.06 (mm of hg) in 
control group.  p-values between group M and D, group M and 
control, group D and control are 0.46, 0.85, 0.44 respectively 
which are statistically not significant to each other. 
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MEAN ARTERIAL BLOOD PRESSURE 
 
 
Baseline 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
89.58±3.49 
 
89.3±4.33 
 
 
0.19 
 
 
 
 
0.84(not 
significant) 
 
GROUP M 
 
GROUP D 
 
89.3±4.33 
 
89.39±3.95 
 
 
0.084 
 
 
0.93(not 
significant) 
 
GROUP D 
 
CONTROL 
 
89.39±3.95 
 
89.95±3.49 
 
 
0.20 
 
 
0.83(not   
significant) 
 
 
 
Loading 
Dose 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
89.5±3.49 
 
83.9±3.55 
 
 
6.16 
 
 
 
 
<0.0001(sign
ificant) 
 
GROUP M 
 
GROUP D 
 
83.9±3.55 
 
73.19±1.86 
 
 
14.63 
 
 
<0.0001(sign
ificant) 
 
GROUP D 
 
CONTROL 
 
73.19±1.86 
 
89.5±3.49 
 
 
22.5 
 
 
<0.0001(sign
ificant) 
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Intraop 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
91.5±2.80 
 
90.87±2.91 
 
 
16.35 
 
 
 
 
<0.0001(sign
ificant) 
 
GROUP M 
 
GROUP D 
 
90.87±2.91 
 
91.32±3.00 
 
 
 
20.41 
 
 
<0.0001(sign
ificant) 
 
GROUP D 
 
CONTROL 
 
91.32±3.00 
 
91.5±2.80 
 
53.2 
 
 
<0.0001(sign
ificant) 
 
 
 
Postop 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
91.5±2.88 
 
90.87±2.91 
 
 
0.40 
 
 
 
 
0.55(not 
significant) 
 
GROUP M 
 
GROUP D 
 
90.87±2.91 
 
91.32±3.00 
 
 
0.57 
 
 
0.84(not 
significant) 
 
GROUP D 
 
CONTROL 
 
91.32±3.00 
 
91.5±2.88 
 
 
0.23 
 
 
0.81(not 
significant) 
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SHOWING DIFFERENCE IN MEAN ARTERIAL BLOOD 
PRESSURE BETWEEN GROUPS 
 
 
 Mean baseline M.A.P is 89.39(mm of hg) in group M, 89.3(mm of 
hg) in group D and 89.58 (mm of hg) in control group. p-values 
between group M and D, group M and control, group D and control 
are 0.93, 0.84, 0.83 respectively which are statistically not 
significant to each other 
 Mean M.A.P during loading dose administration is 83.9(mm of hg) 
in group M, 73.19(mm of hg) in group D and 89.5(mm of hg) in 
control group.  p-values between group M and D, group M and 
control, group D and control are <0.0001,< 0.0001, and <0.0001 
respectively which are statistically significant to each other 
 Mean M.A.P during intra op period is 81.6(mm of hg) in group M, 
71.85 (mm of hg) in group D and 90.72 (mm of hg) in control 
group.  p-values between group M and D, group M and control, 
group D and control are <0.0001, <0.0001, <0.0001 respectively 
which are statistically significant to each other 
 Mean M.A.P during post op period is 90.87(mm of hg) in group M, 
91.32(mm of hg) in group D and 91.5 (mm of hg) in control group.  
p-values between group M and D, group M and control, group D 
and control are 0.55, 0.84, 0.81 respectively which are statistically 
not significant to each other. 
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PULSE RATE 
 
 
Baseline 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
85.6±12.65 
 
80.6±6.605 
 
 
1.919 
 
 
 
 
0.06(not 
significant) 
 
GROUP M 
 
GROUP D 
 
80.6±6.605 
 
81.06±5.63 
 
 
0.2903 
 
 
0.7726(not 
significant) 
 
GROUP D 
 
CONTROL 
 
81.06±5.63 
 
85.6±12.65 
 
 
1.5875 
 
 
0.1178(not 
significant) 
 
 
 
Loading 
Dose 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
91.0±7.51 
 
72.63±5.92 
 
 
10.896 
 
 
 
 
<0.0001 
(significant) 
 
GROUP M 
 
GROUP D 
 
72.63±5.92 
 
68.2 ±4.37 
 
 
1.5858 
 
 
0.0017 
(significant) 
 
GROUP D 
 
CONTROL 
 
68.2±4.37 
 
91.0±7.51 
 
 
5.67 
 
 
<0.0001 
(significant) 
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Intraop 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
95.7±7.27 
 
72.23±5.91 
 
 
13.72 
 
 
 
 
<0.0001 
(significant) 
 
GROUP M 
 
GROUP D 
 
72.23±5.91 
 
64.79±5.88 
 
 
4.88 
 
 
<0.0001 
(significant) 
 
GROUP D 
 
CONTROL 
 
64.79±5.88 
 
95.7±7.27 
 
 
 
30.91 
 
 
<0.0001 
(significant) 
 
 
 
Postop 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
78.1±2.71 
 
77.02±3.22 
 
 
1.4055 
 
 
 
 
0.1652 
(not 
significant) 
 
GROUP M 
 
GROUP D 
 
77.02±3.22 
 
76.1±6.28 
 
 
0.7140 
 
 
0.4781 
(not 
significant) 
 
GROUP D 
 
CONTROL 
 
76.1±6.28 
 
78.1±2.71 
 
 
 
0.2924 
 
 
0.7710 
(not 
significant) 
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SHOWING DIFFERENCE IN PULSE RATE BETWEEN THE 
GROUPS 
 
            
 
 Mean baseline pulse rate is 80.6 in groups M, 81.06 in group D and 
85.6 in control group. p-values between group M and D, group M 
and control, group D and control are 0.77, 0.06, 0.11 respectively 
which are statistically not significant to each other. 
 Mean pulse rate during loading dose administration is 72.63 in 
groups M, 68.2 in group D and 91.0 in control group. p-values 
between group M and D, group M and control, group D and control 
are 0.0017, <0.0001, <0.0001 respectively which are statistically 
significant to each other. 
 Mean pulse rate during intra op period is 72.23 in groups M, 64.79 
in group D and 95.7 in control group.  p-values between group M 
and D, group M and control, group D and control are <0.0001, 
<0.0001, <0.0001 respectively which are statistically significant to 
each other. 
 Mean pulse rate during post op period is 77.02 in groups M, 76.1 in 
group D and 78.1 in control group.  p-values between group M and 
D, group M and control, group D and control are 0.47, 0.16, 0.77 
respectively which are statistically not significant to each other. 
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Sp02 
 
 
Baseline 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
99.37±0.49 
 
99.30±0.46 
 
 
0.567 
 
 
 
 
0.5729(not 
significant) 
 
GROUP M 
 
GROUP D 
 
99.30±0.46 
 
99.26±0.44 
 
 
0.7724 
 
 
0.2904(not 
significant) 
 
GROUP D 
 
CONTROL 
 
99.26±0.44 
 
99.37±0.49 
 
 
 
0.865 
 
 
0.3906(not 
significant) 
 
 
 
Loading 
Dose 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
99.31±0.49 
 
99.3±0.46 
 
 
0.5402 
 
 
 
 
0.5911(not 
significant) 
 
GROUP M 
 
GROUP D 
 
99.3±0.46 
 
99.1±0.44 
 
 
1.6236 
 
 
0.1099(not 
significant) 
 
GROUP D 
 
CONTROL 
 
99.1±0.44 
 
99.31±0.49 
 
 
 
1.5802 
 
 
0.1195(not 
significant) 
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Intraop 
  
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
  
CONTROL 
 
   GROUP M 
 
 
99.3±0.46 
 
99.36±0.49 
 
 
 
0.4840 
 
 
 
0.627(not 
significant) 
 
GROUP M 
 
GROUP D 
 
99.36±0.49 
 
99.14±0.43 
 
 
 
1.8484 
 
 
0.069(not 
significant) 
 
GROUP D 
 
CONTROL 
 
99.14±0.43 
 
99.3±0.46 
 
 
 
1.8148 
 
 
0.0747(not 
significant) 
 
 
 
Postop 
  
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
  
CONTROL 
 
  GROUP M 
 
 
99.36±0.49 
 
99.3±0.46 
 
 
0.486 
 
 
 
 
0.6288(not 
significant) 
 
GROUP M 
 
GROUP D 
 
99.3±0.46 
 
99.4±0.47 
 
 
0.8276 
 
 
0.4113(not 
significant) 
 
GROUP D 
 
CONTROL 
 
99.4±0.47 
 
99.36±0.49 
 
 
 
0.3227 
 
 
0.7481(not 
significant) 
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SHOWING SPO2 DIFFERENCE BETWEEN THE GROUPS 
 
 
 Mean baseline SPO2 is 99.3% in group M, 99.26% in group D and 
99.37% in control group. p-values between group M and D, group 
M and control, group D and control are 0.29, 0.39, 0.57 
respectively which are statistically not significant to each other. 
 Mean SPO2 during loading dose administration is 99.3% in group 
M, 99.1% in group D and 99.31% in control group. p-values 
between group M and D, group M and control, group D and control 
are 0.10, 0.59, 0.11 respectively which are statistically not 
significant to each other. 
 Mean SPO2 during intra op period is 99.36% in group M, 99.14% 
in group D and 99.3% in control group.  p-values between group M 
and D, group M and control, group D and control are 0.06, 0.6, 
0.07 respectively which are statistically not significant to each 
other. 
 Mean SPO2 during post op period is 99.3% in group M, 99.4% in 
group D and 99.36% in control group.  p-values between group M 
and D, group M and control, group D and control are 0.41, 0.62, 
0.74 respectively which are statistically not significant to each 
other. 
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RAMSAY SEDATION SCALE 
 
Time to  
RSS 2 
 
Mean ± Standard 
Deviation 
 
t-value 
 
p-value 
 
GROUP M 
 
    GROUP D 
 
 
5.88±1.14 
 
3.55±0.99 
 
 
8.45 
 
 
 
 
< 0.0001 
(Significant) 
 
 
Time to  
RSS 3 
 
Mean ± Standard 
Deviation 
 
t-value 
 
p-value 
 
GROUP M 
 
    GROUP D 
 
 
8.37±0.90 
 
6.33±0.84 
 
 
9.07 
 
 
 
 
< 0.0001 
(significant) 
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SHOWING MEAN TIME TO ACHEIVE RSS 2 AND RSS 3 IN 
TWO GROUPS                                   
 
 
Mean time to achieve Ramsay Sedation Score of 2 in group M is 5.88 and 
group D is 3.55  
p- value is less than 0.0001 which is statistically significant 
Mean time to achieve Ramsay Sedation Score of 3 in group M is 8.37 and 
group D is 6.33 
p- value is less than 0.0001 which is statistically significant 
 
 
                             
 
 
0
1
2
3
4
5
6
7
8
9
mean time to 
RSS 2
mean time to 
RSS 3
GROUP M
GROUP D
T
I
M
E
 
I
N 
M
I
N
S 
 
 GROUPS  
 
81 
 
FACIAL PAIN SCALE 
 
 CONTROL GROUP M 
F.P.S N % n % 
1-Mild hurt 2 6.7% 23 76.7% 
2-Little hurt 8 26.7% 5 16.7% 
3-Moderate hurt 17 56.7% 2 6.7% 
4-Severe hurt 3 10.0% 0 .0% 
Chi square value -30.2 
Df- 3 
 p-value – <0.0001 (significant) 
 
 GROUP M GROUP D 
F.P.S n           % n           % 
1-Mild hurt 23 76.7% 25 83.3% 
2-Little more hurt 5 16.7% 4 13.3% 
3-Moderate hurt 2 6.7% 1 3.3% 
4-Severe hurt 0 .0% 0 .0% 
Chi square value – 1.635 
Df- 3 
 p-value – 0.651 (not significant) 
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 CONTROL GROUP D 
F.P.S n % n           % 
1-Mild hurt 2 6.7% 25 83.3% 
2-Little hurt 8 26.7% 4 13.3% 
3-Moderate hurt 17 56.7% 1 3.3% 
4-Severe hurt 3 10.0% 0 .0% 
Chi square value – 38.14 
Df- 3 
 p-value - <0.0001 (significant) 
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SHOWING  DIFFERENCE IN WONG BAKER FACIAL PAIN 
SCALE BETWEEN GROUPS 
 
 
 The percentage of patients showing facial pain scale of 1(mild 
hurt) in group M is 76.7%, group D is 83.3% and control is 6.7%  
 The percentage of patients showing facial pain scale of 2 (little 
hurt) in group M is 16.7%, group D is 13.3% and control is 26.7%  
 The percentage of patients showing facial pain scale of 3(moderate 
hurt) in group M is 6.7%, group D is 3.3% and control is 56.7%  
 The percentage of patients showing facial pain scale of 4(severe 
hurt) in group M is 76.7%, group D is 83.3% and control is 6.7% 
 p- value  
- between group M and group D is 0.651 which is statistically not   
significant. 
- between control and group M is < 0.0001 which is statistically 
significant 
- between control and group D is <0.0001 which is statistically   
                 Significant 
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PATIENT MOVEMENT SCALE 
 
 CONTROL GROUP M 
P.M.S n % n %      
1-No move 10 33.4% 22 73.3% 
                     2-Mild 12 40.0% 7 23.3% 
3-Moderate 8 26.6% 1 3.4% 
Chi square value – 11.21 
Df- 2 
 p-value – 0.003(significant) 
 
 GROUP M GROUP D 
P.M.S n %      n % 
1-No move 22 73.3% 27 90.0% 
2-Mild 7 23.3% 2 6.7% 
3-Moderate 1 3.4% 1 3.3% 
Chi square value – 3.48 
Df- 2 
 p-value – 0.17(not significant) 
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 CONTROL GROUP D 
P.M.S n % n % 
1-No move 10 33.4% 27 90.0% 
2-Mild 6 40.0% 2 6.7% 
3-Moderate 7 26.6% 1 3.3% 
Chi square value – 20.3 
Df- 2 
 p-value - <0.0003 (significant) 
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SHOWING PATIENT MOVEMENT SCALE BETWEEN GROUPS                              
 
 
 The percentage of patients showing patient movement scale of 1(no 
move) in group M is 73.3%, group D is 90% and control is 33.4%  
 The percentage of patients showing patient movement scale of 2 
(mild move) in group M is 23.3%, group D is 6.7% and control is 
40%  
 The percentage of patients showing patient movement scale of 
3(moderate move) in group M is 3.3%, group D is 3.4% and 
control is 26.6%  
p- value 
- between group M and group D is 0.17 which is statistically not            
significant 
- between control and group M is 0.003 which is statistically                 
significant 
- between control and group D is <0.0003 which is statistically                
Significant 
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MEAN TIME TO ACHEIVE ALDRETE RECOVERY SCORE 10 
 
TIME TO 
ALDRETE 
RECOVER
Y SCORE 
10 
 
 
Mean ± 
Standard 
Deviation 
 
t-value 
 
p-value 
 
 
CONTROL 
 
GROUP M 
 
 
1.66±0.55 
 
4.07±0.97 
 
 
11.98 
 
 
 
 
<0.0001(sign
ificant) 
 
GROUP M 
 
GROUP D 
 
4.07±0.97 
 
8.09±1.03 
 
 
15.56 
 
 
<0.0001(sign
ificant) 
 
GROUP D 
 
CONTROL 
 
8.09±1.03 
 
1.66±0.55 
 
 
30.30 
 
 
<0.0001(sign
ificant) 
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Mean time to achieve ARS of 10 in group M  is 4.07 min and group D is 
8.09 min and control group is 1.63 min . pvalues between the groups are 
< 0.0001 which is statistically significant.  
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LIKERT LIKE VERBAL RATING SCALE BY SURGEON 
 
 CONTROL 
GROUP 
M(n=30) 
L.V.R.S n % n % 
3-Somewhat 
dissatisfied 
9 
       
30.0% 
4 13.3% 
4-Undecided 13 
       
43.4% 
6 
     
20.0% 
5-Somewhat satisfied 4 13.3% 8 26.7% 
6-Satisfied 4 13.3% 12 40.0% 
Chi square value – 9.8354 
p-value – 0.020 (significant) 
Df-3 
   
 
GROUP M 
(n=30) 
GROUP D 
L.V.R.S n % n % 
3-Somewhat 
dissatisfied 
4 13.3% 3 10.0% 
4-Undecided 6 20.0% 4 13.3% 
5-Somewhat satisfied 8 26.7% 9 30.0% 
6-Satisfied 12 40.0% 14 46.7% 
Chi square value – 4.54 
   p-value – 0.208 (not significant) 
Df-3 
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 CONTROL GROUP D 
L.V.R.S n % n % 
3-Somewhat 
dissatisfied 
9 30.30% 3 10.0% 
4-Undecided 13 43.4% 4 13.3% 
5-Somewhat satisfied 4 13.3% 9 30.0% 
6-Satisfied 4 13.3% 14 46.7% 
 Chi square value – 15.24  
  p-value – 0.0016 (significant) 
Df - 3 
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LIKERT LIKE VERBAL RATING SCALE (LVRS) BY SURGEON 
 
 
 
 The percentage of patients with LVRS OF 3(somewhat 
dissatisfied) in group M is13.3%, group D is 10.0% and control is 
30.0%  
 The percentage of patients with LVRS OF 4 (un decided) in group 
M is 20%, group D is 13.3% and control is 43.4% 
 The percentage of patients with LVRS OF 5 (some what satisfied) 
in group M is 26.7%, group D is 40% and control is 13.3% 
 The percentage of patients with LVRS OF 6 (satisfied) in group M 
is 40%, group D is 46.7% and control is 13.3% 
p value  
- between group M and group D is 0.20 which is statistically not                
significant 
- between control and group M is 0.02 which is statistically                 
significant 
- between control and group D is 0.0016 which is statistically                  
significant 
0
2
4
6
8
10
12
14
Somewhat 
dissatisfied
Undecided Somewhat 
satisfied
Satisfied
CONTROL
GROUP C
GROUP M
N
O 
O
F
 
S
U
B
J
E
C
T
S 
 
 GROUPS SHOWING LIKERT VERBAL RATING SCALE 
 
92 
 
RECALL OF INTRA OP EVENTS 
 
RECALL CONTROL GROUP M 
 n % n % 
                      NO 6 20% 27 50.9%   
YES 24 
       
80% 
3 8.1% 
Chi square value – 29.6 
Df- 1 
 p-value - 0 (significant) 
 
RECALL GROUP M GROUP D 
 n % n % 
                          NO 27 50.9%   26 
      
49.1% 
YES 3 8.1% 4 10.8% 
Chi square value – 0.161 
Df- 1 
 p-value – 0.687 (not significant) 
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RECALL CONTROL GROUP D 
 n % n % 
                          NO 6 20% 26 
      
49.1% 
YES 24 
       
80% 
4 10.8% 
Chi square value – 26.78 
Df- 1 
 p-value - 0 (significant) 
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SHOWING RECALL OF INTRA OP EVENTS BETWEEN 
GROUPS                         
 
 
 50.9% of patients in group M, 49.1% of patients in group D and 
20% of patients in control group had no recall of intra op events 
 8.1%of patients in group M, 10.8% of patients in group D and 80% 
of patients in control group had recall of intra op events 
p- Value  
- between group M and group D is 0.6 which is statistically not 
Significant 
- between control and group M is 0 which is statistically Significant 
- between control and group D is 0 which is statistically Significant 
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POST OP COMPLICATION 
     
Column1 Column2 Column3 Column4  
 
 
 
X
2
=3.6 
 
Df = 2 
 
 
 
 
 
 
p-value 
=0.45(not 
significant) 
 
group m group d control 
hypotension 1  (3%) 2  (6.6%) 0 
bradycardia 0 (0%) 2  (6.6%) 0 
vomiting 2  (6.6%) 2(6.6%) 2 (6.6%) 
Resp 
depression 
0 0 0 
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POST OPERATIVE COMPLICATIONS BETWEEN THE 
GROUPS                  
 
   
There is no significant difference in the incidence of post op 
complications between the groups 
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DISCUSSION 
1. In  our  study,  mean  age  in  Group  M  is  61.56,  group D  is  
60.13  and  control  group  is  60.83. All  3  groups  are  
comparable  in  terms  of  age. 
2. In  our  study,  number  of  male  patients  in  group  M  is  16,  
group  D  is  16  and  control  group  is 14. The  number  of  female  
patients  in  group  M  is  14, group  D  is  14  and  control  group  
is  16. All  3  groups  are  comparable  in  terms  of  sex. 
3. The  mean  weight  of  patients  in  group M  is  61.66,  group  D  is  
61.3  and  control  group  is  61.28.  All  3  groups  are  comparable  
in  terms  of  weight. 
4. Number  of  patients  with  ASA  I  in  group  M   is  15,  group  D  
is  13  and  control  group  is  12. The  number   of  patients  with  
ASA II  in  group  M  is  15,  group  D  is   17  and  control  group  
is  18. All  3  groups  are  comparable  in  terms  of   ASA  PS  
status. 
5. There  was  no  significant  difference  in  the  baseline  systolic  
blood  pressure  and  mean  arterial  pressure  between  the  groups. 
6. I n our study Mean  systolic  blood  pressure  and  mean  of  M.A.P  
during  intraoperative   period  was  significantly  different  
between  group  M and  group  D. [ group M SBP (110.39 mmHg)  
and  M.A.P (90.87 mmHg) VS group D  SBP (99.96 mmHg) and  
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M.A.P (73.19 mmHg) ].  These  2  groups  differ  significantly  
with  that  of  control  group.  The  results  of  our  study  were  
similar  to the  study  conducted  by  ROLO  et al  where  they  
administered  midazolam  in a  loading dose  of  0.05mg/kg  for  
F.O.B  and  also  to  that  of  the  study  conducted  by  WALEED 
M.A  AL  et  al
(37)
  who  administered  inj. Dexmedetomidine  in a  
loading  dose  of  1mg/kg  for  dental  procedures. In  both  the  
studies  maintenance  dose  was  not  given. This  reduction  in  
systolic  blood   pressure  and  M.A.P  was  due  to  reduction  in  
systolic  vascular  resistance  produced  by  the  drugs. Midazolam 
have slightly better hemodynamic stability when compared to that 
of dexmedetomidine. There was no significant difference in the 
post operative blood pressure between the groups. 
7. There was no significant difference in SPO2 between the groups 
throughout the procedure . No patients in the group had a SP02 
below 95% and supplemental O2 was not given in any patient. 
8. In  our  study  mean  heart  rate  significantly  differs  between  
group M and  group  D during  loading dose  administration  and  
intraop  period  [Group M  loading (72.63) , Intraop (72.23)   VS  
group  D ( loading (68.2), intraop (64.7) ]. Heart rate  was  slightly  
lower  in  group D  when  compared  to  midazolam  group. Both  
groups  differ  significantly  from  that  of  the  control  group. In  
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the  study  conducted  by  Richard . R . Riker  et  al  there  was  
significant  incidence  of  bradycardia  in  dexmedetomidine  group  
when  compared  to  that  of  midazolam  group.  In  this  study  the  
patient  received  dexmedetomidine  in  the maintenance  dose  of  
1mcg / kg /hr   which was higher when compared to our study (0.3 
mcg / kg / hr ) and  hence  incidence  of  bradycardia  was  not  
significant in our study. In our study 6 out of 30 patients in group 
D had a heart rate less than 60/min during the intra op period but 
the M.A.P did not fall below 30% of baseline and hence treatment 
was not given. No patients in our study had a heart rate below 5 
0/min 
 
9. In  our  study  mean  time  to  reach  RSS  of  3  was  shorter  in  
dexmedetomidine  group  (6.33 mins)  when  compared  to  that  of  
midazolam  group  (8.37 mins).  In  the  study  conducted  by  
priyanka  sethi  et  al
(39)
  for  ERCP  procedures  the  meantime  to  
reach  RSS 3  was  shorter  for  midazolam  group  when  compared  
to  Dexmedetomidine  as  the  patients  in the study received  
midazolam in a  loading  dose  of  0.03 mg / kg   as  intravenous  
bolus  which was supplemented by 0.5mg incremental doses .But  
in  our study  no supplemental dosing was given during loading 
dose. Hence  this shows that the onset of effect of midazolam can 
100 
 
be made rapid by administrating additional incremental doses 
following loading dose. 
10. In  our  study  though   there  was  no  statistically  significant  
difference  between the  group  M  and group  D  in  Wong  Baker  
facial  pain  scale. Most  of  the  patients in  group  M  (76.7 % )  
and  group  D ( 83.3 % )  had  FPS  of  1 ( mild hurt )  during  
retrobulbar  block  administration  which  was  significantly  
different  from  that  of  the  control  group  in  which  56.7 %  of  
the  patients  had  FPS  of  3 ( i.e  moderate hurt )  and  10 %  of  
the  patients  had  FPS  of  4 ( i.e  severe  hurt ) . Similar  results  
were  observed  in  the  studies  conducted  by  Danies  FC  Water 
M  et  al  who  used  midazolam  in  the  dose  of  0.5 mg i.v  for  
minor  trauma  care  procedures . As in our study with a loading 
dose of 0.05 mg/kg midazolam was found to be equally effective 
with that of dexmedetomidine in attaining  the patient‟s 
cooperation for the placement of retro bulbar block which was not 
actually present in the studies which used lesser loading doses of 
midazolam.( such as Alhashemi et al who used loading dose of 
0.01 to 0.02mg/kg of  midazolam as loading dose 
11. In our study there was no significant difference in the patient 
movement between group M and group D .But patient movement 
was significantly higher in control group. In a study conducted by 
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Alhashemi et al
(26)
 patient movement was higher in midazolam 
group. But they administered only loading dose of midazolam and 
supplemented 0.5 mg of midazolam as and when required. In our 
study we used continuous infusion of midazolam and hence patient 
movement scale of group M was similar to that of 
dexmedetomidine group as the plane of sedation was relatively 
deeper in our study. 
12. Mean time  to  achieve  Aldrete  Recovery  Score  of  10  in  our  
study  was  4.07 mins for group M  and  8.09  mins  for group D 
which  is  significant ( p value < 0.0001 ).  Mean time  was  
prolonged  in  group  D  when  compared  to  group  M .  Similar  
results  were  observed  in  a  study  conducted  by  Alhasemi  et  
al  who  administered  midazolam  in  a  loading  dose  of  0.02 mg 
/ kg  followed  by  0.5 mg  supplementation as and when required   
as  maintenance and administered  Dexmedetomidine   in a loading 
dose of  1mcg / kg  over  10 mins   followed  by  maintenance  dose  
of    0.1- 0.7 mg / kg / hr. 
13. Likert  like   verbal  scale  given  by  the  surgeon  showed  no  
significant  difference  between  the  group  M  and  group  D       ( 
p value < 0.20) . But  there  was  significant  difference  in  surgeon  
satisfaction  when the two groups were compared with that  of  
control  group  in  which  30.3%  of patients showed  “ somewhat  
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dissatisfied ” ( LVRS – 3 ) scale  and   43.3%  showed  “ undecided 
” ( LVRS – 4 ) scale  whereas  40%  of patients in group  M   and   
46.7%  of  the patients in  group  D  showed   “ satisfied ”   LVRS - 
6  scale.  In  the  study  conducted  by  Dhara . A . Vyas   et  al
(40)
  
Surgeon‟s   satisfaction  scale  was  higher  in  group  D  than 
group M  but  in the study  loading  dose  of  Dexmedetomidine   
was  given at  a  higher  dose ( 1 mcg / kg )  when  compared  to  
our  study  ( 0. 3mcg / kg ). In  the  above  study , Surgeons  
satisfaction  scale  was  lower  in  midazolam  group because  of  
the  unwanted  patient  movement  during  the  procedure  who  
received  midazolam in a loading  dose  of  0.01 mg / kg  which  
was  lower  when compared  to  our  study ( 0.05 mg / kg ) .  
Moreover  we  administered  maintenance  infusion  of  midazolam  
which  was  not  given  in  the  above  study. Hence  in our study 
by increasing the loading dose of midazolam  it was possible to 
attain a comparatively deeper plane of sedation which was 
maintained throughout the procedure with the help of maintenance 
infusion.  
14. In  our  study  there  was  no  significant  difference  in  the  recall  
of  unpleasant  intraoperative  event  between   group  D  and  
group  M .  But  in  the  study  conducted  by  Dhara . A . Vyas et 
al ,  group  D   had  lesser  recall  of  events  when  compared  to  
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group  M .  In  this  study  the  maintenance  infusion  of  
midazolam  was  lesser  ( 0.01 mg / kg )  when  compared  to  our  
study  ( 0.05 mg / kg ) . Hence the plane of sedation was higher in 
our study  during the procedure  and the incidence of  „recall of 
unpleasant  intraop events'  was lesser  in our study   
15. In our study there is no significant difference in the incidence of 
complications like vomiting, hypotension, respiratory depression 
and bradycardia between the groups                              
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SUMMARY 
 
We conducted a randomised control trial in 90 patients aged 
between 50 – 70 years and belonged to ASA I and II for cataract surgeries 
by retrobulbar block at K.A.P.V.Govt Medical College,Trichy. 
 
An attempt was made  
 To evaluate the advantage of conscious sedation in cataract surgeries 
which is done with retro bulbar block 
 To compare the effects of midazolam and dexmedetomidine in 
conscious sedation  
 
The patients were divided into three groups namely group M ,group D 
and control group.  
We evaluated - 
1) Anxiolysis of the patient 
2) Patient‟s cooperation  
 in the placement of retro bulbar block and 
 during the procedure 
3) hemodynamic stability 
4) satisfaction of the surgeon 
5)  recovery profile of drugs 
6) incidence of complications 
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We found that conscious sedation was safe and effective in the case 
of cataract surgery and was associated with greater patient „s comfort 
and surgeon‟s satisfaction  when compared to the surgeries which was 
done only with retro bulbar block alone. 
 
Midazolam in a loading dose of 0.05mg/kg and in a maintenance 
dose of 0.03mg/kg was equally effective to dexmedetomidine in the 
aspect of  patient‟s co- operation during retro bulbar block and during 
surgery which was assessed by facial pain scale,patient movement 
scale and surgeon satisfaction scale and recall of intra op events. 
 
Midazolam was slightly better to dexmedetomidine in the aspect of 
better hemodynamic profile. 
 
However mean time to reach RSS  of 3 was rapid with 
dexmedetomidine when compared to midazolam. But time to reach 
Aldrete recovery score 10 was prolonged in dexmedetomidine  when 
compared to midazolam. Both the drugs had no significant 
complications  in the peri operative period. 
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CONCLUSION 
 
We conclude that conscious sedation is safe and effective to 
practise in the case of cataract surgeries and is associated with better 
patient‟s co operation and surgeon‟s comfort when compared to the 
surgeries which are done with retrobulbar block alone. Midazolam 
and dexmedetomidine are equally effective in the aspects of  patient‟s 
co operation and surgeon‟s comfort but midazolam is slightly superior 
to dexmedetomidine in the aspect of better hemodynamic profile 
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TIME TO ALDRETE RECOVERY SCORE 10 
POST OP PARAMETERS 
TIME B.P P.R SPO2    R.S.S COMP 
      
      
      
      
      
 
1) LIKERT LIKE VERBAL RATING SCALE- 
2) ABILITY TO RECALL INTRA OP EVENTS 
YES/NO 
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M.A.P  - Mean  Arterial  Pressure 
P.R  - Pulse  Rate 
S.B.P  - Systolic  Blood  Pressure 
R.S.S  - Ramsay  Sedation  Score 
F.P.S          - Facial  Pain  Score (Wong Baker) 
P.M.S - Patient  Movement  Scale 
A.R.S  -  Aldrete  Recovery  Scale 
L.V.R.S - Likert-Like  Verbal  Rating  Scale 
Hypo  - Hypotension 
Brady  - Bradycardia 
Vomit - Vomiting 
Resp. Dep -  Respiration  Depression  
 
 
NAME AGE SEX ASA GROUP WT
baseline
0min 3 min 6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30 min 60 min 90 min 120 min
MANI 62 M II M 62 134/68 127/74 108/74 102/62 101/64 101/64 102/74 104/64 104/64 128/67 118/64 114/64 112/64 108/64 108/64
SRIDEVI 68 F I M 68 116/64 118/54 114/72 118/64 116/64 114/64 106/64 106/64 104/64 108/64 110/80 110/64 114/80 118/72 122/64
RAJAYYA 64 M II M 70 114/64 112/64 126/64 124/64 130/64 122/64 124/64 122/64 124/64 122/64 101/62 104/62 108/72 106/64 104/61
MUTHAYA 54 M I M 64 130/82 100/60 101/64 102/73 106/72 101/64 102/64 101/64 106/64 108/74 114/64 112/72 112/67 114/64 112/64
SATHI 57 F I M 68 114/62 100/64 98/64 99/62 98/70 99/72 99/74 100/68 100/62 100/70 114/62 104/61 110/58 120/74 124/70
MUKUNTHAN 57 M I M 54 122/74 112/74 114/64 114/62 112/68 114/64 112/72 112/67 114/64 112/64 114/64 114/64 112/64 118/76 116/74
VANATHI 56 F II M 56 120/78 106/70 108/72 104/64 106/66 104/64 104/66 106/64 106/74 108/74 124/64 110/62 108/70 104/70 102/60
VASANTHI 58 M I M 58 130/72 118/64 116/72 114/68 116/72 114/72 106/74 106/66 108/68 106/72 102/57 106/80 106/62 102/70 104/64
MEENA 57 F I M 58 124/64 112/72 116/64 118/70 118/70 112/62 114/64 114/64 112/64 102/70 108/76 106/72 108/70 104/70 102/68
VETIYAN 56 M I M 64 114/76 114/64 116/64 120/72 120/64 120/64 118/72 118/72 118/70 108/72 104/70 106/68 106/64 114/72 114/68
SUMATHY 68 F II M 62 118/72 118/76 118/72 114/70 114/70 114/64 116/64 118/74 108/74 106/64 108/66 110/64 104/64 102/66 108/64
PANDIYAN 64 M II M 68 126/76 116/64 116/72 114/72 118/64 114/64 116/72 114/62 116/78 117/64 114/64 116/72 120/64 120/64 120/70
KUYILI 66 F I M 64 117/64 104/70 108/64 104/64 106/72 112/64 114/64 112/72 112/64 114/64 114/76 110/74 122/72 120/70 122/72
RADHA 64 F II M 70 124/64 100/57 118/78 114/68 114/64 118/68 119/72 120/78 120/72 120/78 108/76 106/72 108/70 104/70 102/68
MUNI 64 M II M 58 130/80 114/72 108/80 104/76 102/66 104/68 104/72 106/70 106/72 104/64 104/64 104/62 102/68 102/64 108/64
KUNTHI 62 F II M 64 134/64 114/64 118/64 114/64 116/64 104/64 102/72 104/70 102/68 102/66 122/72 122/80 122/72 124/64 118/78
RAJENDER 61 M II M 52 126/74 104/64 104/70 106/64 106/66 104/62 106/74 106/72 104/66 104/64 128/70 108/68 110/72 110/72 112/72
KARUPI 64 F II M 60 128/74 118/64 114/64 116/64 114/62 112/64 114/64 114/64 112/64 118/76 112/76 114/70 104/68 106/70 106/72
SEEVAN 61 M II M 66 114/72 1024/64 106/64 112/64 116/64 114/64 114/64 112/64 112/64 118/74 114/64 116/72 114/62 116/78 117/64
LAXMI 64 F II M 64 118/74 102/64 118/72 118/64 128/72 124/74 124/78 118/64 116/72 104/72 112/64 114/64 112/72 112/64 114/64
MURUGAN 66 M I M 67 104/61 106/64 104/62 102/64 104/64 102/66 102/74 104/64 108/68 106/70 114/62 114/70 106/72 106/64 108/70
BEGUM 68 F II M 52 114/67 104/64 106/72 104/66 102/64 102/66 104/64 104/64 104/64 106/64 112/64 114/64 112/72 112/64 114/64
RAYAN 54 M I M 61 118/72 100/76 104/67 106/80 102/64 102/57 106/80 106/62 102/70 104/64 118/68 119/72 120/78 120/72 120/78
GANESAN 54 M I M 64 122/64 100/64 106/80 104/72 106/72 108/76 106/72 108/70 104/70 102/68 104/68 104/72 106/70 106/72 104/64
ANGELINE 62 F II M 56 126/76 106/64 102/64 108/64 102/64 104/64 104/62 102/68 102/64 108/64 118/60 108/72 112/64 102/68 102/64
GNANAVEL 64 M I M 64 116/74 120/76 128/74 124/64 124/64 122/72 122/80 122/72 124/64 118/78 104/64 104/66 106/64 106/74 108/74
MADURAM 58 F I M 68 114/64 101/64 106/64 106/64 106/70 109/64 109/67 100/64 104/60 102/64 114/72 106/74 106/66 108/68 106/72
ANBARASU 56 M I M 56 126/68 104/64 108/64 106/74 112/74 114/64 114/67 112/64 136/64 129/78 112/62 114/64 114/64 112/64 102/70
ADHARSAM 54 M I M 54 118/64 114/64 112/64 106/67 106/72 108/66 110/64 104/64 102/66 108/64 120/64 118/72 118/72 118/70 108/72
MALATHI 62 F II M 58 114/72 116/72 114/64 116/70 118/64 114/64 116/72 120/64 120/64 120/70 104/68 104/72 114/70 110/76 114/72
post op
B.P
loading dose intra op
TIME TO TIME TO
baseline loading intraop post op   RSS 2 RSS 3 baseline
120 min 3min 6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30 min 60 min 90 min 120 min 0
82.5 84.4 82.4 92.4 74 87 76 72 68 67 64 64 62 64 74 76 72 67 70 5 10 99
86.5 81.1 78.4 90.1 78 74 72 71 74 71 71 70 70 72 76 74 78 68 72 5 7 100
90.1 81.3 84.5 92.4 76 76 74 68 69 67 70 72 72 69 88 74 76 71 72 6 10 99
96.5 84.6 86.4 94.4 72 67 67 63 68 65 66 64 66 68 82 82 72 70 76 6 8 99
94.2 86.4 84.5 94.6 84 82 86 97 84 81 74 76 76 68 84 84 72 71 74 8 8 99
90.6 82.1 82.4 90.4 86 76 72 71 69 68 64 66 72 71 86 86 82 84 82 5 7 99
84.7 84.1 80.4 92.4 90 74 72 71 76 72 74 72 77 84 84 72 74 78 80 5 8 99
88.6 80.4 84.6 91.6 84 74 67 68 68 69 65 64 67 66 86 86 84 70 84 6 9 100
84.6 90.1 84.4 94.4 86 74 75 74 72 71 62 67 64 67 84 82 76 72 72 7 9 100
82 84.6 84.3 87.6 88 84 74 76 97 87 84 88 86 89 84 80 74 71 86 7 7 99
84.6 90.3 80.4 90.4 94 74 102 74 76 72 71 72 71 70 82 80 88 68 74 8 9 99
95.4 88.4 82.1 92.4 90 72 74 66 72 74 78 76 76 74 86 80 80 78 82 5 7 99
94.3 86.4 80.6 96.4 84 68 74 69 62 64 66 66 62 64 80 74 72 70 84 6 8 100
94.1 84.1 81.4 94.4 78 68 67 72 67 77 72 80 84 82 88 76 84 72 78 6 9 99
90.4 90.1 84.4 92.2 76 74 72 74 78 77 74 74 76 76 72 80 86 76 72 5 10 99
90.4 82.4 80.1 92.4 72 72 68 67 68 67 76 72 74 84 90 74 64 64 72 6 9 100
84.6 90.4 84.5 90.4 80 64 67 64 67 64 64 66 68 62 88 82 78 72 76 7 8 100
88.7 88.8 82.4 88.7 78 72 79 74 74 71 70 70 70 70 96 76 82 78 86 7 9 99
90.4 84.6 82.4 86.4 76 64 64 64 67 68 64 67 66 66 94 72 76 76 74 8 9 99
92.4 80.4 80.4 94.4 70 64 72 68 74 74 70 76 72 74 94 74 74 82 72 5 9 99
94.6 80.4 80.1 88.2 84 66 66 62 60 68 64 66 64 66 86 84 86 80 84 4 9 99
94.8 84.6 82.1 90.8 86 78 76 70 72 72 73 74 74 75 88 84 74 76 80 5 7 100
90.4 84.6 82.4 86.4 84 74 76 64 70 74 74 75 75 74 87 84 88 76 82 4 8 99
90.4 82.1 82.1 92.1 90 69 69 68 65 65 67 76 74 74 84 86 80 82 82 6 8 99
86.7 80.1 79.1 87.4 84 69 68 68 67 67 72 76 76 77 76 84 84 70 86 6 9 99
94.4 80.3 74.1 90.4 76 82 84 86 82 86 86 84 87 86 86 90 86 72 84 5 9 100
88.7 80.4 80.2 85.2 78 80 86 80 80 87 82 82 80 81 82 72 84 74 81 4 9 99
86.4 82.1 80.4 85.6 78 74 76 70 74 72 76 74 78 80 88 76 80 72 76 5 8 99
84.6 80.3 80.4 90.2 72 68 69 70 70 70 72 72 78 74 88 76 89 72 74 5 9 99
82.4 78.4 78.6 91.4 70 72 70 70 70 69 68 70 71 68 96 78 76 72 74 5 9 100
SPO2
post op
P.R
loading dose intra op
mean M.A.P
F.P.S P.M.S A.R.S L.V.R.S RECALL
hypo brady vomit resp dep
3 min 6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30min 60 min 90min 120 min
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 3 3 NO no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 2 1 4 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 2 5 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 5 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 4 5 NO yes no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 2 4 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 3 5 NO no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 2 2 6 6 NO no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 2 1 5 6 NO no no yes no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 2 5 3 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 4 2 6 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 4 3 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 4 3 4 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 6 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 4 2 3 6 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 2 1 4 6 NO no no yes no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 6 2 6 5 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 5 5 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 5 3 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 4 5 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 4 1 4 6 NO no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 4 1 5 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 5 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 4 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 6 1 6 4 NO no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 2 1 5 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 6 5 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 5 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 6 4 NO no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 100 2 1 6 5 NO no no no no
loading dose intra op
SPO2 POST OP COMPLICATION
postop
NAME AGE SEX ASA GROUP WT
baseline baseline
0min 3 min 6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30 min 60 min 90 min 120 min
rajam 60 F II D 55 130/70 127/74 118/74 112/64 98/74 102/74 104/60 101/65 100/68 100/62 108/70 106/76 104/72 106/75 110/76 84.5
krishnamani 66 M II D 64 127/88 118/54 114/72 104/68 99/71 99/68 98/64 98/64 98/72 98/72 110/80 110/64 112/62 118/72 120/74 88.4
MUTHUSAMI 58 M I D 68 114/62 112/64 108/64 104/61 102/64 101/64 100/61 98/74 98/72 99/60 101/62 104/62 108/72 106/64 104/61 90.1
NATESAN 64 M II D 70 130/82 114/72 112/74 112/64 108/71 106/64 101/64 100/54 100/54 100/61 104/65 106/54 110/68 112/74 112/64 94.2
BHUVANA 56 F I D 54 114/62 140/92 134/74 130/64 121/64 118/70 120/64 118/64 116/58 110/78 114/62 104/61 110/58 112/72 114/64 96.4
MUKUNTHAN 64 M II D 55 124/76 118/76 98/64 94/64 96/61 92/60 94/67 96/64 94/61 97/54 118/62 116/54 108/61 108/64 108/70 92.4
VEERAN 66 F II D 60 120/78 136/74 138/80 138/80 130/74 138/64 136/84 136/72 136/72 138/72 124/64 110/62 108/70 108/64 110/74 86.7
VASAN 64 M II D 64 130/72 118/74 101/64 98/58 96/56 94/56 96/60 96/60 92/64 94/62 128/78 120/76 118/64 114/72 110/68 88.6
MARAN 57 M I D 66 118/76 102/74 94/54 92/60 92/58 90/64 92/64 94/58 99/68 94/64 104/68 117/64 118/64 118/64 120/74 84.6
MARIYAMMAL 57 F I D 68 114/76 104/66 96/64 94/64 94/58 94/60 96/64 96/66 99/70 97/62 104/70 106/68 106/64 114/72 114/68 84.4
SUJATHA 58 F I D 70 116/76 102/64 98/64 96/64 94/54 92/66 94/64 94/64 98/64 98/64 108/76 106/68 110/72 114/76 114/72 86.4
RAJAN 54 M I D 56 124/72 101/58 96/64 94/56 94/60 94/66 96/58 96/61 100/61 102/66 106/72 108/76 110/82 114/80 116/78 92.4
SUBBU 62 M II D 54 117/64 100/54 99/64 94/54 96/60 98/64 98/54 96/54 98/60 99/64 114/76 124/68 122/72 120/70 122/72 94.3
KASI 70 M II D 58 112/74 100/57 98/64 96/60 96/58 100/64 100/64 101/64 102/64 104/64 118/72 116/70 120/74 120/72 124/78 94.1
KALA 64 F II D 54 130/80 114/72 98/61 96/52 96/58 101/64 104/64 104/64 102/64 104/70 108/68 108/72 110/70 108/70 110/72 88.6
MALA 66 F II D 52 132/87 116/64 94/64 92/64 92/60 94/60 92/64 92/58 96/72 99/74 102/68 104/68 106/72 106/68 104/62 92.4
PORIYAN 67 M II D 50 126/74 112/64 96/64 96/56 94/60 94/64 96/60 96/58 98/67 97/64 106/76 108/68 110/72 110/72 112/72 84.6
MASAMMA 58 F I D 64 122/64 100/64 96/64 98/74 96/68 94/62 94/56 92/64 98/76 99/72 102/64 104/70 104/68 106/70 106/72 88.7
SUNDARI 52 F I D 61 114/72 102/64 96/74 96/64 94/58 100/64 98/97 96/64 100/64 99/62 110/62 110/72 110/68 112/70 114/68 90.4
ANNAM 61 F II D 69 108/64 140/88 136/80 136/78 128/72 124/74 124/78 118/64 116/72 114/68 118/72 120/64 120/72 122/70 122/72 92.4
RAMAN 63 M II D 66 104/61 106/64 94/64 96/58 94/60 96/64 94/62 95/66 97/64 98/70 102/64 104/70 106/72 106/64 108/70 94.5
RAMASAMY 67 M II D 64 104/66 104/64 96/61 96/64 98/66 100/75 100/68 104/64 104/64 106/64 108/68 106/68 108/64 106/72 108/68 94.8
NATESAN 58 M II D 63 104/62 100/76 92/64 90/60 90/64 94/64 96/54 98/62 96/64 96/62 96/58 110/74 112/64 112/72 112/80 93.1
SAMIRAJ 59 M II D 64 102/76 100/64 92/64 94/70 92/66 96/64 97/64 98/60 96/64 96/58 108/64 106/70 108/68 108/66 110/70 91.2
MUTHU 54 M I D 59 116/72 100/58 94/56 96/64 94/60 96/64 94/66 94/60 96/64 96/64 108/68 110/72 112/64 112/70 112/64 86.7
RAMAYEE 57 F I D 55 106/74 100/62 96/54 92/66 94/62 98/64 100/64 104/64 102/64 106/64 106/78 108/70 110/68 114/66 116/72 86.7
SIVAGAMI 54 F I D 54 103/74 101/64 96/60 94/64 96/70 99/64 99/64 96/64 96/72 98/68 108/68 106/66 104/70 106/72 116/78 88.7
SIVASU 56 F I D 64 106/76 112/64 94/58 94/58 94/64 96/72 98/64 98/64 94/66 97/64 96/54 106/74 120/74 120/74 122/68 84.4
SUNDARAM 52 M I D 70 116/78 108/66 104/64 100/56 98/64 96/62 96/60 94/62 92/64 94/62 106/64 106/71 112/70 114/71 110/71 84.6
CHINNAYI 60 F II D 68 106/72 106/72 104/56 98/70 96/58 96/60 96/60 96/58 98/62 100/70 100/72 104/72 104/64 110/76 110/78 82.4
post op
B.P
loading dose intra op
mean M.A.P
TIME TO TIME TO
loading intraop post op baseline RSS 2 RSS 3 baseline
0 3min 6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30 min 60 min 90 min 120 min 0 3 min
74.1 71.2 88.4 78 75 71 70 68 62 59 59 61 60 67 72 74 76 76 2 7 99 99
71.1 72.4 91.4 78 81 74 76 64 65 61 64 62 67 68 66 72 74 78 3 5 100 99
72.1 73.1 92.4 81 84 64 66 62 59 59 58 61 64 71 74 72 74 76 3 5 99 99
74.1 71.1 94.4 87 64 61 61 58 57 56 56 56 56 58 71 75 82 80 4 5 100 99
74.1 71.4 94.2 87 112 96 87 84 81 74 76 76 68 71 72 74 84 84 5 6 99 99
72.1 70.4 90.4 82 80 69 94 92 58 58 57 64 70 84 82 82 86 81 3 7 99 99
74.4 71.4 92.4 84 114 112 101 106 104 98 97 87 84 78 64 68 72 76 4 7 100 100
74.6 72.1 92.2 88 76 69 66 64 64 62 59 59 61 70 84 84 86 86 4 8 99 99
73.4 72 94.4 86 82 66 64 58 58 58 64 64 66 72 76 72 82 84 4 5 99 99
73.4 72.4 87.6 84 84 64 64 61 61 60 60 68 70 71 74 76 80 78 5 8 100 99
72.1 72.1 90.4 78 64 72 70 64 62 62 62 64 70 68 72 74 80 76 3 6 99 99
72.4 72.4 92.4 76 72 74 66 58 60 58 56 66 74 78 80 82 80 84 3 6 99 99
71.1 72.1 94.4 74 68 64 59 58 58 56 56 62 64 70 72 72 74 76 6 6 99 98
74.1 70.4 94.4 76 69 68 62 62 60 58 59 59 58 57 72 78 76 74 5 7 99 100
72.1 71.1 92.2 79 74 66 64 62 62 60 62 72 74 76 76 72 80 82 4 7 100 99
74.4 72.1 92.4 75 72 68 64 62 62 63 62 61 59 64 64 72 74 78 4 6 99 100
72.4 72.4 90.4 74 68 64 61 62 61 64 66 68 68 72 78 76 82 82 3 7 99 99
78.4 71.6 94.4 74 72 68 64 64 59 59 60 61 64 78 72 76 76 80 5 6 99 100
70.4 71.4 94.1 66 68 66 64 62 58 58 58 64 72 76 76 74 72 74 5 7 100 100
71.6 72.4 92.4 75 104 112 108 98 98 100 96 92 88 82 74 72 74 68 3 6 99 99
72.1 72.23 93.1 88 78 76 74 70 69 69 69 68 72 80 76 86 84 88 5 7 99 100
72.6 70.4 92.1 87 78 76 74 72 72 64 66 62 64 76 74 80 84 89 6 5 99 99
70.4 71.6 94.4 86 79 76 64 61 61 62 62 70 68 76 86 84 84 86 3 6 100 98
74.1 71.6 92.4 86 88 86 78 70 71 70 68 69 72 82 80 88 86 90 4 6 99 100
76.1 72.3 84.7 84 89 88 80 76 72 72 59 58 64 70 76 76 84 88 4 6 100 100
74.4 72.4 84.6 82 92 84 76 72 70 72 70 60 64 72 88 92 90 88 3 7 99 99
74.6 74.1 85.2 80 90 86 76 74 68 66 66 64 64 74 76 74 68 72 4 7 99 99
76.4 72.4 86.4 87 90 88 72 72 64 62 62 59 62 72 70 72 76 78 5 7 99 99
72.4 71 90.2 88 82 80 75 72 66 64 61 60 64 72 74 76 78 80 5 6 99 99
70.4 72.1 91.4 82 84 74 67 60 56 56 58 59 60 72 74 76 74 76 4 6 99 98
post op
P.R
loading dose intra op
mean M.A.P
loading dose
SPO2
F.P.S P.M.S time to L.V.R.S RECALL
ARS 10 hypo brady vomit resp dep
6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30min 60 min 90min 120 min
98 99 99 99 99 99 99 99 99 99 99 99 99 4 1 8 6 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 6 6 NO no no no no
99 98 98 98 98 98 98 99 100 100 100 100 100 2 1 8 6 NO no no no no
99 99 100 100 100 100 100 100 100 99 99 99 99 2 1 9 5 NO no YES no no
99 99 99 100 100 100 100 99 100 100 100 100 100 4 1 9 6 NO no no no no
99 99 99 99 99 99 99 99 100 100 100 100 100 2 1 8 5 NO no no no no
100 99 98 98 100 100 100 100 100 100 100 100 100 2 1 10 4 NO no no no no
98 99 100 100 100 100 100 100 99 99 99 99 100 2 2 9 6 YES no no no no
98 100 99 99 98 100 100 99 100 100 100 100 100 2 1 8 4 NO no no no no
99 99 100 98 98 100 98 99 99 99 99 99 99 2 1 9 3 NO no no YES no
98 98 100 100 100 100 99 98 99 99 99 99 99 2 1 9 6 YES no no no no
98 99 100 100 100 98 99 98 99 99 99 99 99 2 1 8 5 YES no no no no
98 100 98 98 99 99 99 98 99 99 99 99 99 4 1 7 6 NO no no no no
100 99 99 99 99 99 99 99 100 100 100 100 100 2 1 9 5 NO no YES no no
99 99 99 99 98 98 98 99 99 99 99 99 99 2 1 8 6 NO no no no no
100 100 100 99 100 100 98 99 99 99 99 99 99 4 1 8 5 NO no no no no
100 99 99 99 99 99 99 100 100 100 100 100 100 2 1 9 6 NO no no no no
100 98 100 99 99 99 99 99 99 99 99 99 99 2 2 8 3 NO no no no no
100 99 99 99 99 99 99 99 100 100 100 100 100 2 1 6 5 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 9 5 NO no no no no
100 99 100 99 100 100 98 99 99 99 99 99 99 2 1 9 6 YES no no no no
99 98 100 99 100 100 98 99 100 100 100 100 100 6 1 6 6 NO no no YES no
99 99 100 100 99 99 100 100 99 100 100 100 100 2 1 8 4 NO YES no no no
100 100 99 99 99 99 99 98 99 100 100 100 100 2 1 6 5 NO no no no no
100 100 99 99 99 99 99 99 99 99 99 99 99 2 1 7 6 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 8 6 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 9 3 NO no no no no
99 99 100 100 100 100 100 100 100 100 100 100 100 2 1 7 4 NO YES no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 2 3 9 6 NO no no no no
99 100 98 99 100 98 98 99 99 99 99 99 99 2 1 7 5 NO no no no no
POST OP COMPLICATION
postoploading dose
SPO2
intra op
NAME AGE SEX ASA GROUP WT
baseline baseline
0min 3 min 6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30 min 60 min 90 min 120 min
MARY 62 F II C 62 130/70 127/74 118/74 112/64 138/74 132/74 134/60 131/60 127/64 128/67 108/70 116/76 104/72 106/75 110/76 88.4
MANI 58 M I C 66 127/88 118/54 114/72 118/64 122/67 118/64 128/64 122/64 122/64 126/64 110/80 110/64 114/80 118/72 122/64 86.4
MUNIYAYI 64 F II C 70 114/62 112/64 126/64 130/74 130/64 132/64 128/64 132/64 138/64 133/64 101/62 104/62 108/72 106/64 104/61 90.1
NATESAN 66 M II C 68 130/82 114/72 112/74 112/64 108/71 106/64 101/64 100/54 100/54 100/61 104/62 106/54 112/64 112/74 112/64 94.2
SANTHI 54 F I C 56 114/62 140/92 134/74 130/64 121/64 118/70 120/64 118/64 116/58 110/78 114/62 104/61 110/58 120/74 124/70 92.4
MUKUNTHAN 66 M II C 54 124/76 118/76 128/64 124/76 126/71 122/64 134/72 136/72 134/61 136/78 118/62 116/54 108/61 108/64 108/70 91.4
VASUKI 68 F II C 64 120/78 136/74 138/80 138/80 130/74 138/64 136/84 136/72 136/72 138/72 124/64 110/62 108/70 104/70 102/60 92.1
VASAN 64 M II C 66 130/72 121/74 121/72 128/67 136/74 134/74 126/72 126/66 128/72 136/72 128/78 120/76 118/64 114/72 110/68 94.4
MEENA 58 F I C 64 118/76 120/76 124/66 122/60 122/64 122/64 122/64 124/64 122/64 122/70 106/80 107/64 118/64 118/64 120/74 84.6
MINNAL 58 F I C 66 114/76 114/64 116/64 120/72 120/64 120/64 118/72 118/72 118/70 108/72 104/70 106/68 106/64 114/72 114/68 84.4
SUMITRA 62 F II C 68 116/76 118/76 118/72 114/70 114/70 114/64 116/64 118/74 108/74 106/64 108/76 106/68 108/62 104/77 114/72 86.4
PANDIYAN 64 M II C 58 124/72 120/72 126/80 124/88 128/60 124/60 126/72 126/64 120/70 120/74 106/72 108/76 110/82 114/80 116/78 92.4
SEETHA 52 F I C 52 117/64 124/70 128/67 124/72 126/78 124/72 124/64 122/72 122/68 128/72 114/76 110/74 122/72 120/70 122/72 94.3
RAVI 68 M II C 56 112/74 100/57 118/78 114/68 118/78 118/68 119/72 120/78 120/72 120/78 118/72 116/70 120/74 120/72 124/78 94.1
KAMALAM 64 F II C 64 130/80 114/72 118/76 124/72 132/74 134/74 136/74 136/74 138/74 124/74 108/68 108/72 110/70 108/70 110/72 88.6
DURGA 66 F II C 58 132/87 124/64 122/64 122/72 120/74 128/74 128/80 124/64 128/72 128/78 102/68 110/64 116/72 116/68 114/62 92.4
RAJAN 68 M II C 60 126/74 132/64 136/76 137/68 137/68 134/62 136/72 134/74 134/80 128/69 128/70 108/68 110/72 110/72 112/72 84.6
KALIYAYI 60 F II C 54 122/64 120/64 120/64 120/76 122/72 120/74 120/76 120/74 120/68 118/76 112/76 114/70 104/68 106/70 106/72 88.7
MUPIDATI 62 F I C 61 114/72 102/64 96/74 126/74 126/66 124/64 120/78 120/74 120/76 118/74 110/62 110/72 110/68 102/70 104/68 84.5
SORNAM 64 F II C 69 108/64 130/87 118/72 118/64 128/72 124/74 124/78 118/64 116/72 104/72 122/72 120/64 120/72 122/70 122/72 92.4
RAMAN 56 M I C 66 104/61 106/64 104/62 102/64 104/64 102/66 102/74 104/64 108/68 106/70 114/62 114/70 106/72 106/64 108/70 88.7
NEHRU 68 M II C 64 104/66 104/64 106/72 104/66 102/64 102/66 104/64 104/64 104/64 106/64 108/68 106/68 108/64 102/72 104/68 94.8
VASANTHI 58 F I C 64 104/62 100/76 104/67 106/80 102/64 102/57 106/80 106/62 102/70 104/64 102/64 110/74 112/64 102/72 102/80 93.1
KARUPAIYA 67 M II C 63 102/76 100/64 106/80 104/72 106/72 108/76 106/72 108/70 104/70 102/68 118/94 116/70 108/68 108/66 110/70 86.4
MARISAN 64 M II C 69 116/72 128/76 136/78 136/87 134/85 135/76 134/74 134/72 136/80 128/74 118/60 108/72 112/64 102/68 102/64 86.7
VIJAYA 54 F I C 55 106/74 120/76 128/74 124/64 124/64 122/72 122/80 122/72 124/64 118/78 116/72 118/70 110/68 114/66 116/72 91.4
SELVAM 58 M I C 54 103/74 101/64 106/64 106/64 106/70 109/64 109/67 100/64 104/60 102/64 104/72 106/66 102/64 108/68 118/67 88.7
ANBURAJ 56 M I C 54 106/76 112/64 127/64 128/64 128/72 138/74 136/84 136/72 136/64 129/78 118/74 116/72 120/74 120/74 122/68 90.2
AROKIYAM 54 M I C 54 116/78 124/80 126/72 124/76 126/72 126/72 124/64 124/64 122/74 124/72 104/72 104/68 112/70 114/71 112/64 86.4
KANCHANA 64 F II C 58 106/72 136/76 134/76 130/72 130/78 134/88 136/78 132/74 124/64 118/72 104/68 104/72 114/70 110/76 114/72 84.4
post op
B.P
loading dose intra op
mean M.A.P
TIME TO TIME TO
loading intraop post op baseline RSS 2 RSS 3 baseline
0 3min 6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30 min 60 min 90 min 120 min 0 3 min
90.4 91.2 86.4 98 96 98 94 98 96 96 94 94 94 78 72 70 74 74         -         - 99 99
90.2 94 90.2 98 91 96 95 74 96 95 94 98 98 86 78 72 74 78         -         - 100 100
90.1 92.4 92.4 94 99 98 82 84 109 104 110 102 104 91 76 72 74 76         -         - 99 99
89.4 90.8 94.4 87 74 96 92 92 98 87 87 88 84 70 72 76 72 82         -         - 99 99
88.7 89.6 94.2 88 82 86 97 84 81 74 76 76 68 71 72 74 84 84         -         - 99 99
86.4 90.34 88.4 96 100 106 94 92 108 110 106 104 106 84 82 82 76 86         -         - 99 99
92.4 88.4 92.4 84 104 102 101 106 104 98 97 87 84 78 74 80 72 90         -         - 100 100
88.4 88.6 92.2 88 97 89 96 84 85 84 81 82 87 90 84 84 86 84         -         - 100 100
87.4 92.1 96.4 86 102 86 94 101 100 102 102 100 97 82 76 72 82 86         -         - 100 100
87.6 92.4 86.4 84 84 94 104 97 87 84 88 86 89 91 74 86 70 88         -         - 99 99
89.4 91.4 90.4 78 74 102 107 97 94 106 105 104 100 84 88 74 80 94         -         - 99 99
88.4 90.6 92.4 76 102 74 66 102 100 108 76 76 74 78 80 82 80 90         -         - 99 99
90.1 91.4 94.4 74 68 74 59 72 74 106 106 102 104 80 72 84 74 84         -         - 100 100
92.1 90.4 92.4 76 88 107 102 97 77 72 80 84 82 92 84 78 86 78         -         - 99 99
94.4 90.6 91.4 79 74 82 94 99 97 98 94 97 96 86 86 72 80 76         -         - 99 99
95.4 90.4 92.4 86 72 68 97 98 97 96 96 98 84 84 64 72 74 72         -         - 100 100
96.4 92.1 95 74 54 97 104 97 104 104 106 108 102 92 78 76 84 80         -         - 100 100
94.2 91.1 94.4 74 72 99 104 98 101 100 100 100 97 86 82 86 76 78         -         - 99 99
95.4 91.4 94.1 66 64 99 104 97 98 94 96 96 96 64 76 74 82 76         -         - 99 99
94.1 91.4 92.1 75 94 92 108 99 98 100 96 92 88 84 74 72 74 70         -         - 99 99
94.4 92.3 93.1 88 96 96 102 100 108 104 106 102 106 80 86 84 84 84         -         - 99 99
92.1 92 91.7 87 98 96 102 102 104 105 105 105 105 76 74 80 86 86         -         - 100 100
90.2 93.4 92.4 86 94 96 64 100 104 104 105 105 104 96 88 82 84 84         -         - 100 100
86.4 91.4 92.4 94 88 86 78 101 105 107 106 104 104 90 80 82 88 90         -         - 99 99
84.5 89.4 88.4 95 89 88 80 87 88 92 96 98 97 84 84 86 84 84         -         - 99 99
84.4 88.4 86.4 92 92 94 96 92 86 86 84 87 86 86 86 84 78 76         -         - 100 100
86.4 87 85.2 90 90 96 100 100 97 102 102 100 101 82 84 81 72 78         -         - 99 99
84.6 86.4 89.1 87 90 96 100 104 102 106 104 101 100 88 80 76 74 78         -         - 99 99
89.4 88.7 90.2 96 82 90 95 92 96 94 91 98 94 88 89 74 78 72         -         - 99 99
88.4 92.1 94 92 94 98 94 90 96 98 98 98 96 96 76 74 76 70         -         - 100 100
loading dose
SPO2
post op
P.R
loading dose intra op
mean M.A.P
F.P.S P.M.S A.R.S L.V.R.S RECALL
hypo brady vomit resp dep
6 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 1 min 30min 60 min 90min 120 min
99 99 99 99 99 99 99 99 99 99 99 99 99 6 1 1 3 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 4 1 2 4 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 2 1 4 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 1 2 4 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 1 1 5 YES yes no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 2 1 5 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 4 1 2 5 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 6 2 2 6 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 4 1 2 6 NO no no yes no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 3 3 3 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 3 2 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 1 2 3 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 4 2 2 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 8 1 1 4 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 4 3 1 6 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 8 1 2 6 YES no no yes no
100 100 100 100 100 100 100 100 100 100 100 100 100 8 3 2 5 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 4 1 1 5 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 2 3 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 4 3 2 5 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 2 1 1 6 NO no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 4 1 2 4 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 6 3 2 4 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 1 1 5 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 2 2 4 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 6 1 1 4 NO no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 2 2 5 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 3 1 4 YES no no no no
99 99 99 99 99 99 99 99 99 99 99 99 99 6 1 1 6 YES no no no no
100 100 100 100 100 100 100 100 100 100 100 100 100 6 1 2 5 YES no no no no
postoploading dose intra op
SPO2 POST OP COMPLICATION
